Methods and compounds for preparing spiro oligomers
By using Fmoc groups to protect amines and copper-complexed amino acid groups in the preparation of spirocyclic oligomers, the problem of low efficiency in existing technologies has been solved, and high-yield and high-purity multi-kilogram scale production has been achieved.
Patent Information
- Application Number
- CN202380030873.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-08
- Filing Date
- 2023-02-08
- Publication Date
- 2024-11-26
AI Technical Summary
Existing technologies are inefficient and involve cumbersome steps in the preparation of spirocyclic oligomers, making large-scale production difficult.
A method is employed to contact a compound of formula I with R1X, R1C(O)H or R1C(O)R2 in the presence of a reducing agent, thereby forming a spirocyclic oligomer by protecting the amine with a Fmoc group and using copper to complex the amino acid group, followed by a rigidification treatment under non-strict conditions.
It has achieved the preparation of spirocyclic oligomers with high yield and high purity, and can be produced in multi-kilogram batches, simplifying the preparation steps and improving efficiency.
Smart Images

Figure CN119032097A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 307,869, filed on February 8, 2022, the disclosure of which is incorporated herein in its entirety by the accompanying reference.
[0003] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0004] This invention was made in cooperation with the Government under DE-EE0008321 awarded by the U.S. Department of Energy and HDTRA1-16-1-0047 awarded by the Defense Threat Reduction Agency. The Government has certain rights in this invention. Technical Field
[0005] The present disclosure relates to methods and compounds for preparing spirocyclic oligomers. Background Art
[0006] Dipeptides, also known as spiro-oligomers, are ladder-shaped oligomers or polymers formed from amino acids. Spiro-oligomers can be used as therapeutic agents, catalysts, sensors, antibody mimics, and in nanotechnology. Their shape can be customized based on the stereochemistry and sequence of the monomers. In the synthesis of dipeptides, amino acids are used to form a diketopiperazine ring to produce a spiro-oligomer.
[0007] The standard approach for synthesizing spirocyclic oligomers is via a stepwise method by sequentially adding a single diamino acid at each stage of the synthesis. Although this type of method allows stereochemical control, they are relatively inefficient. For example, such methods usually produce no more than a few milligrams of spirocyclic oligomers, the steps are difficult to carry out, and the method often requires long hours and a lot of labor.
[0008] Therefore, there is a need in the art for an efficient method of preparing spirocyclic oligomers via simple steps and / or in high yield. The present invention addresses this unmet need in the art. Summary of the invention
[0009] In some aspects, the present invention provides a method comprising reacting a compound of formula I with R 1 X, R 1 C(O)H or R 1 C(O)R 2 contacting in the presence of a reducing agent and under conditions and for a period of time effective to produce a compound of formula II:
[0010]
[0011] Among them, R 1 , R 2 ,X,R 4, x and z are as defined herein;
[0012]
[0013] Wherein, y is an integer of 0 or 1; provided that when the compound of formula I is combined with R 1 When X reacts, y is an integer 0 and R 2 Does not exist.
[0014] In other aspects, the invention provides compounds, such as spirocyclic oligomers, produced using the methods described herein.
[0015] In a further aspect, the present invention provides a process for preparing compounds of formula I, III, IV, VII and XV, wherein R 1 , R 2 , R 4 , R 5 , x, y and z are as defined herein:
[0016]
[0017]
[0018] In yet other aspects, the present invention provides a compound of formula II or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 5 and y is as defined herein:
[0019]
[0020] In yet other aspects, the present invention provides compounds, such as:
[0021]
[0022] Other aspects and embodiments of the invention will become apparent from the following detailed description of the invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The following detailed description of various embodiments of the present invention will be better understood when read in conjunction with the accompanying drawings. For the purpose of illustrating the present invention, illustrative embodiments are shown in the accompanying drawings. However, it should be understood that the present invention is not limited to the precise arrangements and means of the embodiments shown in the accompanying drawings.
[0024] Figure 1 Depicts the use of temporary Cu 2+ Schematic illustration of the complexation strategy for fluorenylmethoxycarbonyl (Fmoc) protection of functionalized bis-amino acid building blocks and the efficient multi-kilogram-scale synthesis of bis-amino acid precursors.
[0025] Figure 2 Schematic diagram depicting the synthesis of the Cbz building block.
[0026] Figure 3 A schematic diagram of the synthesis of the Fmoc building block is depicted.
[0027] Figure 4 Schematic representation of the synthesis of functionalized building blocks and Pfp esters is depicted.
[0028] Figure 5 Schematic representation of the chemical structures of spirocyclic oligomers (a) T2, (b) T3, (c) T4, and (d) the modeled structure of T1 based on ROESY correlation and GAFF energy minimization with CANDO.
[0029] Figure 6 Depicted is a schematic representation of the synthesis of functionalized spirocyclic oligomer T1 with selected ROESY correlations and modeled structures.
[0030] Figure 7 A schematic diagram of the previously reported compound S2a (Levins, CG et al., Journal of the American Chemical Society 2003, 125(16), 4702-4703) and the corresponding representative 1 H NMR spectrum.
[0031] Figure 8 A schematic diagram of the previously reported compound S3a (Levins, CG et al., Journal of the American Chemical Society 2003, 125(16), 4702-4703) and the corresponding representative 1 H NMR spectrum.
[0032] Fig. 9 A schematic diagram of previously reported compound 2a (Levins, CG et al., Journal of the American Chemical Society 2003, 125(16), 4702-4703) and the corresponding representative 1 H NMR spectrum.
[0033] Fig.10 Depicted is a schematic diagram of the previously reported compound S2b (Levins, CG et al., Journal of the American Chemical Society 2003, 125(16), 4702-4703) and the corresponding representative 1H NMR spectrum.
[0034] Fig.11 Depicted is a schematic diagram of the previously reported compound S3b (Levins, CG et al., Journal of the American Chemical Society 2003, 125(16), 4702-4703) and the corresponding representative 1 H NMR spectrum.
[0035] Fig.12 A schematic diagram of previously reported compound 2b (Levins, CG et al., Journal of the American Chemical Society 2003, 125(16), 4702-4703) and the corresponding representative 1 H NMR spectrum.
[0036] Fig.13 A schematic diagram of compound 4a (3S,5S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-3-amino-5-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid and the corresponding representative 1 H NMR and 13 C NMR spectrum.
[0037] Fig.14 A schematic diagram of compound 4b (3R,5S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-3-amino-5-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid and the corresponding representative 1 H NMR and 13 C NMR spectrum.
[0038] Fig.15 A schematic diagram of compound 4c (3R,5R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-3-amino-5-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid and the corresponding representative 1 H NMR and 13 C NMR spectrum.
[0039] Fig.16 A schematic diagram of compound 4d (3R,5S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-3-amino-5-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid and the corresponding representative 1 H NMR and 13 C NMR spectrum.
[0040] Fig.17A schematic diagram of compound 5a (3S,5S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-5-(tert-butoxycarbonyl)-3-((naphthalen-2-ylmethyl)amino)pyrrolidine-3-carboxylic acid and the corresponding representative 1 H NMR and 13 C NMR spectrum.
[0041] Fig.18 Depicted is a schematic diagram of the bisamino acid 5b(3R,5S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-5-(tert-butoxycarbonyl)-3-(isopentylamino)pyrrolidine-3-carboxylic acid and the corresponding representative 1 H NMR and 13 C NMR spectrum.
[0042] Fig.19 A schematic diagram of compound 5c (3R,5R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-5-(tert-butoxycarbonyl)-3-((pyridin-4-ylmethyl)amino)pyrrolidine-3-carboxylic acid and the corresponding representative 1 H NMR and 13 CNMR spectrum.
[0043] Fig. 20 A schematic diagram of compound 5d (3S,5R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-5-(tert-butoxycarbonyl)-3-((3,4-dichlorobenzyl)amino)pyrrolidine-3-carboxylic acid and the corresponding representative 1 H NMR and 13 C NMR spectrum.
[0044] Fig.21 A schematic diagram of compound 6a 1-((9H-fluoren-9-yl)methyl)2-(tert-butyl)4-(perfluorophenyl)(2S,4S)-4-((naphthalen-2-ylmethyl)amino)pyrrolidine-1,2,4-tricarboxylate and the corresponding representative 1 H NMR and 13 CNMR spectrum.
[0045] Fig. 22 A schematic diagram of compound 6b 1-((9H-fluoren-9-yl)methyl)2-(tert-butyl)4-(perfluorophenyl)(2S,4R)-4-(isopentylamino)pyrrolidine-1,2,4-tricarboxylate and the corresponding representative 1 H NMR and 13 C NMR spectrum.
[0046] Fig.23A schematic diagram of compound 6c 1-((9H-fluoren-9-yl)methyl)2-(tert-butyl)4-(perfluorophenyl)(2R,4R)-4-((pyridin-4-ylmethyl)amino)pyrrolidine-1,2,4-tricarboxylate and the corresponding representative 1 H NMR and 13 C NMR spectrum.
[0047] Fig.24 A schematic diagram of compound 6d 1-((9H-fluoren-9-yl)methyl)2-(tert-butyl)4-(perfluorophenyl)(2R,4S)-4-((3,4-dichlorobenzyl)amino)pyrrolidine-1,2,4-tricarboxylate and the corresponding representative 1 H NMR and 13 CNMR spectrum.
[0048] Fig.25 Representative images of the synthesis of Fmoc building blocks are depicted during (a) hydrogenolysis of the Cbz building block with Pd / C, (b) Fmoc protection with Fmoc-Cl, (c) removal of Pd / C with a diatomaceous earth column, and (d) removal of Cu with an EDTA solution. 2+ and allowing the product to precipitate. (d) isolating the product by vacuum filtration.
[0049] Fig.26 A representative HPLC chromatogram of crude, unpurified T1 at 220 nm is depicted.
[0050] Fig. 27 Representative QTOF LCMS results of T1 are depicted: (top) LC chromatogram at 220 nm; (middle) total ion current chromatogram; (bottom) mass spectrum, where the theoretical monoisotopic peaks and observed monoisotopic peaks are in red and black, respectively.
[0051] Fig.28 Representative QTOF LCMS results of T2 are depicted: (top) LC chromatogram at 220 nm; (middle) total ion current chromatogram; (bottom) mass spectrum, where theoretical and observed monoisotopic peaks are in red and black, respectively.
[0052] Fig.29 Representative QTOF LCMS results of T3 are depicted: (top) LC chromatogram at 220 nm; (middle) total ion current chromatogram; (bottom) mass spectrum, where theoretical and observed monoisotopic peaks are in red and black, respectively.
[0053] Fig.30Representative QTOF LCMS results of T4 are depicted: (top) LC chromatogram at 220 nm; (middle) total ion current chromatogram; (bottom) mass spectrum, where theoretical and observed monoisotopic peaks are in red and black, respectively. DETAILED DESCRIPTION
[0054] The present invention provides an efficient method for preparing spirocyclic oligomers. In contrast to methods in the art, the methods described herein allow the preparation of a larger number of spirocyclic oligomers with a high degree of preorganized structure. By doing so, a wide variety of building blocks of different length sequences can be assembled to produce an almost unlimited number of highly preorganized molecules with designable shapes and functional group displays.
[0055] The present invention uses a key and unique step that provides the ability to prepare spirocyclic oligomers and intermediates thereof in high yield. Initially, the method allowed the intermediates to be prepared in batches of 40-50 grams, which far exceeds the output recorded in the art. After the method is improved, multi-kilogram batches of intermediates and products can be prepared.
[0056] Among the features, a unique step involves the use of an ingenious Fmoc group to protect amines at key positions in the molecule. To date, a wide variety of protecting groups have been used in methods for preparing spiro oligomers. However, the inventors have found that simply replacing traditional protecting groups with Fmoc groups is not efficient and greatly reduces the yield of spiro oligomers, which is already very low. Fmoc protecting groups can also be easily functionalized using a wide range and number of functional groups via simple steps. Another key step involves the use of metals such as copper to selectively complex amino acid groups, thereby allowing the selective protection of other amines with Fmoc groups. These key steps result in high yields (i.e., >90%) and greater than 95% purity.
[0057] Finally, once the spiro oligomer is formed, it can be smoothly rigidified in a minimal amount of time using non-stringent conditions.
[0058] definition
[0059] In the present invention, unless the context clearly dictates otherwise, the singular forms "a", "an", and "the" include plural references, and a reference to a particular value includes at least that particular value. Thus, for example, a reference to "a material" is a reference to at least one of such material and equivalents thereof known to those skilled in the art, and so forth.
[0060] When a value is expressed as an approximation by using the descriptor "about", it will be understood that the specific value forms another embodiment. Generally, the term "about" is used to represent an approximation, which may vary depending on the desired properties that the disclosed subject matter attempts to obtain and should be interpreted in the specific context of its use based on its function. In some aspects of the present invention, "about" refers to a range of values of ±10% of the value. For example, "about 10" refers to "9 to 11" and "10". Those skilled in the art will be able to interpret it as usual. In some cases, the number of significant figures for a specific value can be a non-limiting method for determining the scope of the word "about". In other cases, the grades used in a series of values can be used to determine the expected range available for the term "about" for each value. Where present, all ranges are inclusive and combinable. That is, the value described in the reference range includes each value in the range. It should be understood that, in the case of providing a parameter range, the present invention also provides all integers and their deciles within the range. For example, "20-40 mg" includes 20.0 mg, 20.1 mg, 20.2 mg, 20.3 mg, etc., up to 40.0 mg.
[0061] When a list is shown, it should be understood that each individual element of the list and each combination of the list should be interpreted as a separate embodiment unless otherwise specified. For example, a list of embodiments shown as "A, B, or C" should be interpreted to include embodiments "A", "B", "C", "A or B", "A or C", "B or C", or "A, B, or C".
[0062] It should be understood that certain features of the present invention described herein in the context of separate embodiments for clarity may also be provided in combination in a single embodiment. That is, unless clearly incompatible or excluded, each separate embodiment is considered to be combinable with any other embodiment and such combination is considered to be another embodiment. On the contrary, the various features of the present invention described in the context of a single embodiment for brevity may also be provided separately or in any sub-combination. It should be further noted that the claims may be written to exclude any optional elements. Therefore, this statement is intended to be used as a prerequisite for the use of exclusive terms such as "solely" and "only" or the use of "negative" limitations together with the narration of the claim elements. Finally, although the embodiment may be described as part of a series of steps or part of a more general structure, each of the steps itself may also be considered as an independent embodiment.
[0063] As used herein, the term "halogen" refers to Cl, F, Br or I. In some aspects, halogen is Cl. In other aspects, halogen is F. In further aspects, halogen is Br. In still other aspects, halogen is I.
[0064] As used herein, "C0" refers to the absence of carbon atoms. 0-6 Alkyl OH refers to -OH and C 1-6 alkyl.
[0065] As used herein, the term "alkyl" refers to an aliphatic hydrocarbon containing 1 to 12 carbon atoms, i.e., C 1-12 In some embodiments, the alkyl group is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc. In other embodiments, the alkyl group is C 1-8 In a further embodiment, the alkyl group is C 1-6 In a further embodiment, the alkyl group is C 1-4 In yet other embodiments, the alkyl group is C 1-4 Alkyl. Examples of alkyl include methyl, ethyl, propyl (e.g., n-propyl, isopropyl), butyl (e.g., sec-butyl, tert-butyl, isobutyl), 3-pentyl, hexyl, heptyl, octyl, nonyl, and decyl. As described herein, alkyl can be unsubstituted or substituted, i.e., optionally substituted. In some aspects, alkyl is substituted with two substituents. In further aspects, alkyl is substituted with one substituent. In other aspects, alkyl is substituted with three substituents. In further aspects, alkyl is unsubstituted.
[0066] As used herein, the term "alkenyl" refers to an alkyl group containing one or more carbon-carbon double bonds. In some embodiments, the alkenyl group contains one, two, or three carbon-carbon double bonds. In other embodiments, the alkenyl group contains one carbon-carbon double bond. In further embodiments, the alkenyl group is C 2-6 In yet other embodiments, alkenyl is C 2-4 In a further embodiment, alkenyl is C 3-4 Alkenyl. Non-limiting exemplary alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, hexenyl and -CH=C(CH3)2. Alkenyl groups can be unsubstituted or substituted. In some embodiments, alkenyl groups are substituted with two substituents. In further embodiments, alkenyl groups are substituted with one substituent. In yet other embodiments, alkenyl groups are substituted with three substituents. In further embodiments, alkenyl groups are unsubstituted.
[0067] As used herein, the term "alkynyl" refers to an alkyl group containing one or more carbon-carbon triple bonds. In some embodiments, the alkynyl group contains one, two, or three carbon-carbon triple bonds. In other embodiments, the alkynyl group contains one carbon-carbon triple bond. In further embodiments, the alkynyl group is C 2-6 In yet other embodiments, alkynyl is C2-4 In a further embodiment, alkynyl is C 3-4 Alkynyl. Among them, non-limiting exemplary alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc. Alkynyl can be unsubstituted or substituted. In some embodiments, alkynyl is substituted with two substituents. In further embodiments, alkynyl is substituted with one substituent. In yet other embodiments, alkynyl is substituted with three substituents. In further embodiments, alkynyl is unsubstituted.
[0068] As used herein, the term "alkoxy" refers to an optionally substituted alkyl group as defined herein that contains an oxygen atom within the group. In some embodiments, the alkoxy group is an alkyl group attached to a terminal oxygen atom. In other embodiments, the alkoxy group is a C 1-6 In a further embodiment, the alkoxy group is C 1-4 Examples of alkoxy groups include methoxy (OCH3), ethoxy (OCH2CH3 or CH2OCH3), propoxy (e.g., -O n Pr, -O i Pr), or butoxy (e.g., -O n Bu, -O i Bu, -O s Bu, -O t Bu). Alkoxy may be unsubstituted or substituted. In some embodiments, alkoxy is substituted with two substituents. In further embodiments, alkoxy is substituted with one substituent. In still other embodiments, alkoxy is substituted with three substituents. In further embodiments, alkoxy is unsubstituted.
[0069] As used herein, the term "cycloalkyl" refers to a saturated or partially unsaturated cyclic aliphatic hydrocarbon containing 1 to 3 rings and 3 to 12 carbon atoms, i.e., C 3-12 Cycloalkyl or C 3-12 In some embodiments, the cycloalkyl has two rings. In other embodiments, the cycloalkyl has one ring. In further embodiments, the cycloalkyl is saturated. In still other embodiments, the cycloalkyl has one or two double bonds. In further embodiments, the cycloalkyl is C 3-8 In yet further embodiments, the cycloalkyl group is C 3-7 In yet other embodiments, the cycloalkyl group is C 3-7 In other embodiments, the cycloalkyl group is C 3-6 In a further embodiment, the cycloalkyl group is C 3-6Cycloalkyl. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl and cyclopentenyl. Cycloalkyl can be unsubstituted or substituted. In some embodiments, cycloalkyl is substituted with two substituents. In further embodiments, cycloalkyl is substituted with one substituent. In yet other embodiments, cycloalkyl is substituted with three substituents. In further embodiments, cycloalkyl is unsubstituted.
[0070] As used herein, the term "cyanoalkyl" refers to an alkyl group substituted with one or more CN groups. In some embodiments, the cyanoalkyl group contains one CN substituent. In other embodiments, the cyanoalkyl group contains two CN substituents. 1-6 Examples of cyanoalkyl include CH2CN, CH2CH2CN, CHCNCH3 without limitation.
[0071] As used herein, the term "haloalkyl" refers to an alkyl group substituted with one or more halogens. In some embodiments, the haloalkyl group contains one or more F, i.e., a fluoroalkyl group. In other embodiments, the haloalkyl group contains one halogen (e.g., F). In further embodiments, the haloalkyl group contains two halogens (e.g., F). In yet other embodiments, the haloalkyl group contains three halogens (e.g., F). 1-6 Examples of haloalkyl include CH2F, CHF2, CF3, CH2CFH2, CH2CF2H, CH2CH2CF3 without limitation.
[0072] As used herein, the term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens. In some embodiments, the haloalkoxy group comprises one or more F, i.e., a fluoroalkyl group. In other embodiments, the haloalkoxy group comprises one halogen (e.g., F). In further embodiments, the haloalkoxy group comprises two halogens (e.g., F). In yet other embodiments, the haloalkoxy group comprises three halogens (e.g., F). Wherein, C 1-6 Examples of the haloalkoxy group include OCH2F, OCHF2, OCF3, OCH2CFH2, OCH2CF2H, OCH2CH2CF3 without limitation.
[0073] As used herein, the term "aryl" refers to a monocyclic or bicyclic unsaturated ring system having 5 to 14 carbon atoms, i.e., C 5-14 In some embodiments, the aryl group has 6-12 carbon atoms, i.e., C 6-12 In a further embodiment, the aryl group has 6 to 10 carbon atoms, i.e., C 6-10In other embodiments, the aryl group has 6-8 carbon atoms, i.e., C 6-8 Aryl. Examples of aryl include phenyl, naphthyl (1-naphthyl, 2-naphthyl), phenanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylalkenyl and fluorenyl without limitation. In some embodiments, aryl is phenyl or naphthyl. The term "aryl" also includes phenyl fused to a cycloalkyl. Aryl can be unsubstituted or substituted. In some embodiments, aryl is an optionally substituted phenyl.
[0074] As used herein, the term "heteroaryl" refers to a monocyclic or bicyclic aromatic ring system having 5 to 14 ring atoms, i.e., a 5-14 membered heteroaryl. The heteroaryl group comprises carbon atoms and one or more heteroatoms, wherein the heteroatoms are oxygen, nitrogen and sulfur. In some embodiments, the heteroaryl group comprises 1, 2, 3 or 4 oxygen, nitrogen and / or sulfur. In other embodiments, the heteroaryl group comprises three heteroatoms. In further embodiments, the heteroaryl group comprises two heteroatoms. In yet other embodiments, the heteroaryl group comprises one heteroatom. In yet other embodiments, the heteroaryl group is a 5-10 membered heteroaryl group. In further embodiments, the heteroaryl group is a 5 or 6 membered heteroaryl group. In other embodiments, the heteroaryl group is a 5 membered heteroaryl group. In further embodiments, the heteroaryl group is a 6 membered heteroaryl group. Examples of heteroaryl groups include thienyl (e.g., thien-2-yl, thien-3-yl), benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furanyl (e.g., 2-furanyl, 3-furanyl, 4-furanyl), benzofuranyl, pyranyl, thienyl, benzofuranyl, isobenzofuranyl, benzoxazolyl, chromenyl, xanthenyl, pyrrolyl (e.g., pyrrol-2-yl, pyrrol-3-yl), imidazolyl (e.g., imidazol-2-yl, imidazol-4-yl, 1-methylimidazole yl), pyrazolyl (e.g., pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl), pyridinyl (e.g., pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl), pyrazinyl (e.g., pyrazin-2-yl, pyrazin-3-yl, pyrazin-5-yl, pyrazin-6-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl), pyridazinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl (e.g., 1,8- -naphthyridinyl), cinnolinyl, triazolyl (e.g., 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl), thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl), oxadiazolyl (e.g., 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl), quinazolinyl, pteridinyl, 4H-carbazolyl, carbazolyl, β-carbazolyl, -carbolyl, phenanthridinyl, acridinyl, phenanthrolinyl, phenazinyl, thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, 2-methylthiazolyl), isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl), phenothiazolyl, isoxazolyl (e.g., isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, 3,5-dimethylisoxazolyl), furazanyl, pyrazolo[1,5-a]pyridinyl, benzisothiazolyl, imidazo[1,5-a]pyridinyl (e.g., imidazo[1,5-a]pyridin-1-yl), pyrrolo[1,2]pyridazinyl (e.g., pyrrolo[1,2]pyridazin-5-yl, pyrrolo[1,2]pyridazin-6-yl), benzo[d]thiazolyl (e.g., benzo[d]thiazol-3-yl, benzo[d]thiazol-2-yl), benzo[d]imidazolyl (e.g., benzo[d]imidazol-2-yl), benzo[d]oxazolyl (e.g., benzo[d]oxazol-2-yl), benzo[c]isoxazolyl (e.g., benzo[d] [c]isoxazol-3-yl), isothiazolyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, phenoxazinyl, triazinyl, indolizinyl, quinolyl, 1,2,3,4-tetrahydroquinolyl, isoquinolyl, 1,2,3,4-tetrahydroisoquinolyl, benzo[b]thienyl, 1H-indazolyl (e.g., indazol-3-yl), benzothiazolyl, 4H-quinolizinyl, quinoxalinyl, phenothiazinyl, oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, oxazol-5-yl), or 2-pyrenyl. The term "heteroaryl" also includes N-oxides. Heteroaryl can be unsubstituted or substituted. In some embodiments, heteroaryl is substituted with two substituents. In further embodiments, heteroaryl is substituted with one substituent. In yet other embodiments, heteroaryl is substituted with three substituents. In further embodiments, the heteroaryl group is unsubstituted. Substitution may occur on any available carbon or heteroatom (e.g., nitrogen) or both, as long as the substituent valence permits. Heteroaryl groups also include heteroaryl groups with fused optionally substituted cycloalkyl groups or fused optionally substituted heterocyclic groups.
[0075] As used herein, the term "heterocyclyl" refers to a non-aromatic saturated or partially unsaturated group containing one, two or three rings with 3-14 ring members, i.e., a 3-14 membered heterocyclyl. The heterocyclyl contains carbon atoms and one or more oxygen atoms, sulfur atoms and / or nitrogen atoms, which may be oxidized or quaternized. In some embodiments, the ring CH2- is substituted with -C(=O)-. The term "heterocyclyl" also includes groups with fused optionally substituted aryl groups, for example, indolinyl or chroman-4-yl. In some embodiments, the heterocyclyl is C 4-6Heterocyclic group.Heterocyclic group can be optionally connected to the rest of the molecule by any available carbon or heteroatom.Examples of heterocyclic groups include azetidinyl (for example, azetidinyl -1- base, azetidinyl -2- base, azetidinyl -3- base), dioxanyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, indolinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, 2-pyrazolyl, pyrazolidinyl, trithianyl, indolizinyl, benzo [b] thienyl, 1H- indazolyl, benzothiazolyl, 4H- quinolizinyl, quinolyl, 1,2,3,4- tetrahydroquinolyl, isoquinolyl, 1,2,3,4- tetrahydroisoquinolyl, quinoxalinyl, phenothiazinyl.Heterocyclic group can be unsubstituted or substituted.In some embodiments, heterocyclic group is substituted by two substituents. In further embodiments, the heterocyclyl is substituted with one substituent. In yet other embodiments, the heterocyclyl is substituted with three substituents. In still further embodiments, the heterocyclyl is unsubstituted.
[0076] Any of the groups / substituents described above or herein may be substituted by one or more of the following groups: CN, halogen, NO2, OH, NH2, C 1-6 Alkoxy, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)(C 1-6 alkyl), aryl, O-aryl, C 1-6 AlkylSH, -C(O)C 1-6 Alkyl, -C(O)OC 1-6 alkyl, -C(O)aryl, -C(O)Oaryl, -C(O)heteroaryl, -C(O)Oheteroaryl, -C(O)heterocyclyl, -C(O)Oheterocyclyl, C 1-6 Cyanoalkyl, C 3-8 Cycloalkyl, C 1-6 Halogenated alkoxy, C 1-6 Haloalkyl, heteroaryl, heterocyclic, -C 1-6 Alkyl (heterocyclic), -C 1-6 Alkyl (aryl), -C 1-6 Alkyl (heteroaryl), -C 1-6 Alkyl (cycloalkyl), C 1-6 Hydroxyalkyl, C(O)NH2, or OC(O)NH2.
[0077] As used herein, the term "nucleobase" refers to optionally substituted adenine, cytosine, guanine, thymine or uracil. In some embodiments, the nucleobase is a purine base such as adenine or guanine. In other embodiments, the nucleobase is a pyrimidine base such as cytosine, uracil or thymine. In a further embodiment, the nucleobase is a modified nucleobase such as a modified purine nucleobase or a modified pyrimidine nucleobase. The example of the modified nucleobase includes hypoxanthine, xanthine, 7-methylguanine, inosine, xanthine, 7-methylguanosine, 5,6-dihydrouracil, 5-methylcytosine, 5-hydroxymethylcytosine, dihydrouridine or 5-methylcytidine. In some other embodiments, the nucleobase is an artificial nucleobase such as isoguanine, isocytosine, 2-amino-6-(2-thienyl)purine or pyrrole-2-carboxaldehyde.
[0078] As used herein, the term "amino acid" refers to natural amino acids or non-natural amino acids. In some embodiments, amino acids are natural amino acids. In certain aspects, amino acids are arginine (Arg), histidine (His), lysine (Lys), aspartic acid (Asp), glutamic acid (Glu), serine (Ser), threonine (Thr), asparagine (Asn), glutamine (Gln), cysteine (Cys), selenocysteine (Sec), glycine (Gly), proline (Pro), alanine (Ala), valine (Val), isoleucine (Ile), leucine (Leu), methionine (Met), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp) or pyrrolysine. In further embodiments, amino acids are non-natural amino acids. In certain embodiments, the amino acid is 4-aminobenzoic acid (PABA), alloisoleucine, allothreonine, carboxyglutamic acid, cystathionine, D-alanine, dehydroalanine, D-glutamic acid, diaminopimelic acid, leucine, glycine betaine, homocysteine, homonorleucine, homoserine, hydroxyglycine, hydroxyproline, hydroxyputrescine, isoserine, isovaline, lanthionine, N-ethylalanine, N-ethylglycine, N-ethyl β-alanine, N-isopropylglycine, N-methylalanine, N-methyl β-alanine, norleucine, norvaline. In some embodiments, amino acids are protected with suitable protecting groups as described herein.
[0079] As used herein, the term "sugar" refers to a simple sugar or complex sugar as known in the art. In some embodiments, sugar is a monosaccharide such as glucose, fructose or galactose. In other embodiments, sugar is a disaccharide or a disaccharide (two monosaccharides are connected by a glycosidic bond) such as sucrose, lactose or maltose. In some embodiments, sugar is protected with a suitable protecting group herein.
[0080] Scope: Throughout the present invention, various aspects of the present invention may be presented in range form. It should be understood that the description in range form is merely for convenience and brevity, and should not be interpreted as an immutable limitation on the scope of the present invention. Therefore, the description of a range should be considered to specifically disclose all possible sub-ranges as well as individual values within the range. For example, the description of a range (e.g., 1 to 6) should be considered to specifically disclose sub-ranges, such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as individual values within the range, such as 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
[0081] method
[0082] The present invention relates in part to methods for preparing compounds of formula II:
[0083]
[0084] In the compounds of Formula II, y is an integer of 0 or 1. In some embodiments, y is an integer of 0. In other embodiments, y is an integer of 1. In these compounds, x is an integer of 1 or 2. In some embodiments, x is an integer of 1. In other embodiments, x is an integer of 2. Similarly, z is an integer of 1 or 2. In some embodiments, z is an integer of 1. In other embodiments, z is an integer of 2. In further embodiments, x and z are not both 2.
[0085] R 1 is an optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 In some embodiments, R 1 is an optionally substituted C 1-6 In other embodiments, R 1 is an optionally substituted C 2-6 In a further embodiment, R 1 is an optionally substituted C 2-6 In yet other embodiments, R 1 is an optionally substituted aryl group, for example, a phenyl group. 2 is absent, H, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 In some embodiments, R 2In other embodiments, R 2 is H. In a further embodiment, R 2 is an optionally substituted C 1-6 In other embodiments, R 2 is an optionally substituted C 2-6 In a further embodiment, R 2 is an optionally substituted C 2-6 In yet other embodiments, R 2 is an optionally substituted aryl group, for example, a phenyl group. 1 and R 2 Can be substituted by one or more groups. 1 and / or R 2 is independently substituted by 1, 2, 3, 4 or 5 groups. 1 and R 2 If substituted, the substituents may be the same or different.
[0086] In certain embodiments, R 1 and R 2 is independently substituted by: C 0-6 Alkyl OH, C 0-6 Alkyl SH, C 0-6 Alkyl NH2, C 0-6 Alkyl-OC 0-6 Alkyl, C 0-6 Alkyl-SC 0-6 Alkyl, C 0-6 Alkyl C(O)OH, C 0-6 Alkyl C(O)(C 1-6 Alkyl), C 0-6 Alkyl C(O)O(C 1-6 Alkyl), C 0-6 Alkyl N3, C 0-6 Alkyl C(O)NH2, C 0-6 Alkyl-C(O)N(C 1-6 alkyl)OH, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 5-7 cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, -NHC(NH2)(=N(C 0-6 alkyl), -NHC(NH2)(=S(C 0-6wherein any carbon atom of the alkyl, alkenyl or alkynyl group is optionally substituted by a heteroatom, wherein the heteroatom is O, S, SO, SO2 or NR 7 In other embodiments, R 1 and R 2 Independently by C 0-6 In a further embodiment, R 1 and R 2 Independently by C 0-6 In yet other embodiments, R 1 and R 2 Independently by C 0-6 In a further embodiment, R 1 and R 2 Independently by C 0-6 Alkyl-OC 0-6 Alkyl such as -OC 1-6 In other embodiments, R 1 and R 2 Independently by C 0-6 Alkyl-SC 0-6 Alkyl such as -SC 1-6 In a further embodiment, R 1 and R 2 Independently by C 0-6 In yet other embodiments, R 1 and R 2 Independently by C 0-6 Alkyl C(O)(C 1-6 Alkyl) such as -C(O)(C 1-6 alkyl), or for example -CH2-C(O)(C 1-6 In yet further embodiments, R 1 and R 2 Independently by C 0-6 Alkyl C(O)O(C 1-6 In other embodiments, R 1 and R 2 Independently by C 0-6 Alkyl N3, such as N3 or such as -CH2N3, is substituted. In a further embodiment, R1 and R 2 Independently by C 0-6 In yet other embodiments, R 1 and R 2 Independently by C 0-6 Alkyl-C(O)N(C 1-6 Alkyl)OH such as -C(O)N(C 1-6 In yet further embodiments, R 1 and R 2 C is independently optionally substituted 3-7 In other embodiments, R 1 and R 2 C is independently optionally substituted 5-7 In a further embodiment, R 1 and R 2 is independently optionally substituted aryl, such as phenyl, p-cresol, 1-methoxy-benzyl, naphthyl, 4-methyl-phenol or 1-methoxy-4-methyl-benzene), or such as phenyl. In yet other embodiments, R 1 and R 2 is independently optionally substituted heteroaryl, such as imidazolyl, 2-pyrenyl, 1-methylimidazolyl, indolyl, pyridyl, such as 2-pyridyl, 3-pyridyl or 4-pyridyl, triazolyl, or imidazolyl. In yet further embodiments, R 1 and R 2 R is independently an optionally substituted heterocyclic group such as azetidinyl, dioxanyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, indolyl, oxetanyl, tetrahydrofuranyl, tetrahydrothiophenyl, 2-pyrazolinyl, pyrazolidinyl, trithianyl, indolizinyl, benzo[b]thienyl, 1H-indazolyl, benzothiazolyl, 4H-quinolizinyl, quinolyl, 1,2,3,4-tetrahydroquinolyl, isoquinolyl, 1,2,3,4-tetrahydroisoquinolyl, quinoxalinyl, phenothiazinyl. In other embodiments, R 1 and R 2 are independently -NHC(NH2)(=N(C 0-6 In a further embodiment, R 1 and R 2 are independently -NHC(NH2)(=S(C0-6 In some embodiments, R 1 and R 2 It can be protected with a removable protecting group. For example, a reactive nitrogen can be protected with an Alloc group.
[0087] In yet other embodiments, R 1 and R 2 are independently nucleobases. Examples of such nucleobases include, but are not limited to, guanine, adenine, cytosine, thymine, or any combination thereof.
[0088] In yet other embodiments, R 1 and R 2 Independently, it is amino acid, sugar, or any combination thereof. In some embodiments, amino acid is β-amino acid. Examples of amino acids include, but are not limited to, arginine (Arg), histidine (His), lysine (Lys), aspartic acid (Asp), glutamic acid (Glu), serine (Ser), threonine (Thr), asparagine (Asn), glutamine (Gln), cysteine (Cys), selenocysteine (Sec), glycine (Gly), proline (Pro), alanine (Ala), valine (Val), isoleucine (Ile), leucine (Leu), methionine (Met), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp), pyrrolysine, or any combination thereof.
[0089] In a further embodiment, R 1 and R 2 join together with the carbon to which they are attached to form C 3-8 Cycloalkyl is, for example, cyclopropyl, cyclobutyl or cyclopentyl. 1 and R 2 are linked together to form a cyclopropyl group. In other embodiments, R 1 and R 2 are linked together to form a cyclobutyl group. In a further embodiment, R 1 and R 2 In yet other embodiments, R 1 and R 2 Linked together to form a cyclohexyl group.
[0090] In certain embodiments, any carbon atom of an alkyl, alkenyl, or alkynyl group is optionally replaced by O, S, SO, SO2, or NR 7In some embodiments, any carbon atom of an alkyl, alkenyl or alkynyl group is optionally replaced by an O heteroatom. In further embodiments, any carbon atom of an alkyl, alkenyl or alkynyl group is optionally replaced by an S heteroatom. In yet other embodiments, any carbon atom of an alkyl, alkenyl or alkynyl group is optionally replaced by an SO group. In further embodiments, any carbon atom of an alkyl, alkenyl or alkynyl group is optionally replaced by an SO2 group. In other embodiments, any carbon atom of an alkyl, alkenyl or alkynyl group is optionally replaced by an NR 7 For example, NH, or N(C 1-4 alkyl), or for example NCH3.
[0091] R 7 H, C 1-4 Alkyl, C 3-4 Alkenyl, C 3-4 Alkynyl, or C 1-4 A bridged alkyl group wherein the bridge is formed between the nitrogen atom and the carbon atom of the chain containing the heteroatom, thereby forming a ring, wherein the ring is optionally connected to Ar 1 In some embodiments, R 7 is H. In other embodiments, R 7 C 1-4 In a further embodiment, R 7 C 3-4 In yet other embodiments, R 7 C 3-4 In a further embodiment, R 7 C 1-4 A bridged alkyl group wherein the bridge is formed between the nitrogen atom and the carbon atom of the heteroatom-containing chain, thereby forming a ring, wherein the ring is optionally connected to Ar 1 Condensed.
[0092] Ar 1 C 3-6 In some embodiments, Ar 1 C 3-6 In other embodiments, Ar 1 is aryl, for example phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, or anthracenyl. In a further embodiment, Ar 1 is a heterocyclic group, such as azetidinyl, aziridinyl, piperidinyl, or azepanyl. In other embodiments, Ar 1is a heteroaryl group, for example, an acridinyl group, a benzimidazolyl group, a benzothiazolyl group, a benzo[b]furanyl group, a benzo[b]thienyl group, a carbazolyl group, a cinnolinyl group, a furanyl group, for example, a 2-furanyl group or a 3-furanyl group, an imidazolyl group, a 1H-indazolyl group, an indolizinyl group, for example, a 3H-indolyl group, an indolyl group, an isoindolyl group, an isoquinolinyl group, an isoxazolyl group, a 1,8-naphthyridinyl group, an oxadiazolyl group, for example, a 1,2,3-oxadiazolyl group, an oxazolyl group, a phenazinyl group, a phenothiazinyl group, a phenoxazinyl group, a pteridinyl group, a purinyl group, a pyrazinyl group, Pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, pyridazinyl, pyrimidinyl, pyridyl, such as 2-pyridyl, 3-pyridyl or 4-pyridyl, pyrrolyl, 4H-quinolizinyl, quinolyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, 1,3,4-thiadiazolyl, thiazolyl, 1,2,3-triazolyl, 1,3,5-triazinyl, 1,3,5-trithianyl, or thienyl, such as 2-thienyl or 3-thienyl.
[0093] Ar 1 Optionally substituted by one or more of the following groups: H, halogen, OH, NO2, -SO3H, CF3, OCF3, C 1-6 Alkyl groups such as CH3, C 2-6 Alkenyl, C 1-6 Alkoxy such as OCH3, OC 3-4 alkenyl, -O-benzyl, -O-phenyl, 1,2-methylenedioxy, -NR 5 R 6 、-C(O)OH、-C(O)(C 1-6 alkyl), C(O)O(C 1-6 alkyl), carboxamides such as C(O)NH(C 1-6 alkyl), -C(O)NH(C 3-5 alkenyl), -C(O)N(C 1-6 Alkyl)(C 1-6 alkyl), -C(O)(C 3-5 Alkenyl)(C 3-6 alkyl), morpholinyl, piperidinyl, -O-Ar 2 、-CH2-(CH2) q -Ar 2 、-O-(CH2) q -Ar 2 、-(CH2) q -O-Ar 2 , or -CH=CH-Ar 2 . R 5 and R 6 Independently H, C 1-6 Alkyl, C 3-6 Alkenyl, C3-6 Alkynyl, or benzyl. 2 is 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazolyl, quinolyl, 3,5-dimethylisoxazolyl, 2-methylthiazolyl, thiazolyl, 2-thienyl, 3-thienyl or pyrimidinyl. q is an integer from 0 to 2.
[0094] In the compound of formula II, X is a leaving group. One skilled in the art will be able to readily determine a suitable leaving group for use as "X". In some embodiments, X is a halogen or a sulfonate. In other embodiments, X is a halogen, such as chlorine, fluorine, or bromine. In further embodiments, X is a sulfonate, such as p-toluenesulfonate (OTs), methanesulfonate (OMs), or trifluoromethanesulfonate (OTf). 4 In some embodiments, R 4 C 1-6 alkyl or 4-{N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino}benzyl ester (DMab). In other embodiments, R 4 C 1-6 Alkyl, for example tert-butyl.
[0095] In certain aspects, the compound of Formula II has the structure of Formula II-A.
[0096]
[0097] In a further aspect, the compound of formula II has a structure of formula II-A. In other aspects, the compound of formula II has a structure of formula II-B. In a further aspect, the compound of formula II has a structure of formula II-C.
[0098] By reacting a compound of formula I with R 1 X, R 1 C(O)H or R 1 C(O)R 2 The compound of formula II is prepared by contacting in the presence of a reducing agent under conditions and for a time effective to produce the compound of formula II:
[0099]
[0100] In some embodiments, when the compound of Formula I is combined with R 1 When X reacts, y is an integer 0 and R 2 Does not exist.
[0101] The organic solvent for preparing the compound of formula II can be selected by those skilled in the art. In some embodiments, the organic solvent is a polar organic solvent. In other embodiments, the organic solvent is an alcohol solvent such as methanol, an ether solvent such as tetrahydrofuran or ethyl acetate. The reducing agent for forming the compound of formula II can be selected by those skilled in the art. In some embodiments, the reducing agent is NaBH3, NaBH3CN or Na(CH3COO)3BH. In other embodiments, the reducing agent is NaBH3CN.
[0102] In some aspects, the compound of Formula I has the structure of Formula IA:
[0103]
[0104] In a further aspect, the compound of Formula I has a structure of Formula IA. In another aspect, the compound of Formula I has a structure of Formula IB. In a further aspect, the compound of Formula I has a structure of Formula IC.
[0105] The compound of formula I can be prepared by contacting a compound of formula III with a chelating agent for a period of time and under conditions effective to produce a compound of formula I:
[0106]
[0107] Wherein, M is a transition metal with a +2 oxidation state. In some embodiments, M is vanadium, manganese, iron, cobalt, nickel, copper or zinc. In other embodiments, M is copper. In further embodiments, M is manganese. In still other embodiments, M is iron. In further embodiments, M is cobalt. In other embodiments, M is nickel. In further embodiments, M is zinc.
[0108] The chelating agent for preparing the compound of formula I can be selected by those skilled in the art. In some embodiments, the chelating agent is ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA) or hydroxyethylethylenediaminetriacetic acid (HEDTA), or a salt thereof. In further embodiments, the chelating agent is Na2EDTA·H2O or CaNa2EDTA. In other embodiments, the chelating agent is H2S, thiazolidinethione, glycine and / or other chelating agents.
[0109] The organic solvent for preparing the compound of formula I can be selected by those skilled in the art. In some embodiments, the organic solvent is a polar organic solvent. In other embodiments, the organic solvent is an ether solvent, a chlorinated organic solvent, or a combination thereof. In a further embodiment, the organic solvent is an ether solvent such as methyl tert-butyl ether. In other embodiments, the organic solvent is a chlorinated organic solvent, such as chloroform. In a further embodiment, the organic solvent is a mixture of methyl tert-butyl ether and chloroform. When a combination / mixture of solvents is utilized, the ratio is from about 1:1 to about 1:5. In some embodiments, the ratio of methyl tert-butyl ether to chloroform is from about 1:1 to about 1:5.
[0110] In some aspects, the compound has the structure of Formula III-A, Formula III-B, Formula III-C, Formula III-D, Formula III-E, Formula III-F, or Formula III-G:
[0111]
[0112]
[0113]
[0114] In further aspects, the compound of formula III has a structure of formula III-A. In other aspects, the compound of formula III has a structure of formula III-B. In further aspects, the compound of formula III has a structure of formula III-C. In still other aspects, the compound of formula III has a structure of formula III-D. In still further aspects, the compound of formula III has a structure of formula III-E. In other aspects, the compound of formula III has a structure of formula III-F. In further aspects, the compound of formula III has a structure of formula III-G.
[0115] The compound of formula III is prepared by contacting a compound of formula IV with 9-fluorenylmethoxyphosgene for a period of time and under conditions effective to produce the compound of formula IV:
[0116]
[0117] The organic solvent used to prepare the compound of formula IV is a polar organic solvent. In some embodiments, the organic solvent is ethyl acetate or any solvent of similar polarity that allows the reaction to occur. In some embodiments, the organic solvent allows the reaction to occur. In some aspects, the compound of formula IV has a structure of formula IV-A, formula IV-B, formula IV-C, formula IV-D, formula IV-E, formula IV-F, or formula IV-G:
[0118]
[0119] In further aspects, the compound of formula IV has a structure of formula IV-A. In other aspects, the compound of formula IV has a structure of formula IV-B. In further aspects, the compound of formula IV has a structure of formula IV-C. In still other aspects, the compound of formula IV has a structure of formula IV-D. In still further aspects, the compound of formula IV has a structure of formula IV-E. In other aspects, the compound of formula IV has a structure of formula IV-F. In further aspects, the compound of formula IV has a structure of formula IV-G.
[0120] The compound of formula IV is prepared by contacting a compound of formula V with a metal (II) source under conditions and for a time and under conditions effective to produce a compound of formula IV:
[0121]
[0122] In some embodiments, the metal (II) source is a Ni (II) source or a copper (II) source. In other embodiments, the metal source is a copper (II) source such as a copper (II) salt. In further embodiments, the metal (II) source is a Ni (II) source. In other embodiments, copper (II) salts such as copper chloride or copper sulfate. The solvent can be selected by those skilled in the art. In some embodiments, the solvent is water. In other embodiments, the solvent is optionally a mixture of water and one or more organic co-solvents.
[0123] In some aspects, the compound of Formula V has the structure of Formula VA, Formula VB, or Formula VC:
[0124]
[0125] In a further aspect, the compound of Formula V has a structure of Formula VA. In another aspect, the compound of Formula V has a structure of Formula VB. In a further aspect, the compound of Formula V has a structure of Formula VC.
[0126] The compound of formula II can be contacted with a compound of formula VI-A, formula VI-B or formula VI-C, an activating agent and a base to provide an intermediate:
[0127]
[0128] In certain embodiments, the compound of formula II is contacted with a compound of formula VI-A. In other embodiments, the compound of formula II is contacted with a compound of formula VI-B. In further embodiments, the compound of formula II is contacted with a compound of formula VI-C.
[0129] In some embodiments, AA is an optionally substituted amino acid. Amino acids can be selected by those skilled in the art. In some aspects, AA is a natural amino acid or a non-natural amino acid. In some aspects, AA is arginine (Arg), histidine (His), lysine (Lys), aspartic acid (Asp), glutamic acid (Glu), serine (Ser), threonine (Thr), asparagine (Asn), glutamine (Gln), cysteine (Cys), selenocysteine (Sec), glycine (Gly), proline (Pro), alanine (Ala), valine (Val), isoleucine (Ile), leucine (Leu), methionine (Met), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp) or pyrrolysine. In some aspects, AA is glycine. In other aspects, AA is alanine. In further aspects, AA is valine. In yet other aspects, AA is leucine. In further aspects, AA is isoleucine. In other aspects, AA is proline. In further aspects, AA is serine. In still other aspects, AA is threonine. In still further aspects, AA is asparagine. In other aspects, AA is glutamine. In further aspects, AA is cysteine. In still other aspects, AA is methionine. In still further aspects, AA is phenylalanine. In other aspects, AA is tyrosine. In further aspects, AA is tryptophan. In still other aspects, AA is aspartic acid. In still further aspects, AA is glutamic acid. In other aspects, AA is histidine. In further aspects, AA is lysine. In still other aspects, AA is arginine. In still further aspects, AA is selenocysteine. In other aspects, AA is pyrrolysine. In further aspects, AA is beta-alanine.
[0130] AA can also be selected from unnatural amino acids, such as PABA, alloisoleucine, allothreonine, carboxyglutamic acid, cystathionine, D-alanine, dehydroalanine, D-glutamic acid, diaminopimelic acid, leucine, glycine betaine, homocysteine, homonorleucine, homoserine, hydroxyglycine, hydroxyproline, hydroxyputrescine lysine, isoserine, isovaline, lanthionine, N-ethylalanine, N-ethylglycine, N-ethyl β-alanine, N-isopropylglycine, N-methylalanine, N-methyl β-alanine, norleucine, norvaline, N-propylglycine, In some aspects, AA is PABA. In other aspects, AA is allo-isoleucine. In further aspects, AA is allo-threonine. In yet other aspects, AA is carboxyglutamic acid. In further aspects, AA is cystathionine. In other aspects, AA is D-alanine. In further aspects, AA is dehydroalanine. In still other aspects, AA is D-glutamic acid. In still further aspects, AA is diaminopimelic acid. In still further aspects, AA is leucine. In other aspects, AA is glycine betaine homocysteine. In further aspects, AA is homonorleucine. In still other aspects, AA is homoserine. In still further aspects, AA is hydroxyglycine. In other aspects, AA is hydroxyproline. In further aspects, AA is hydroxyputrescine lysine. In still other aspects, AA is isoserine. In still further aspects, AA is isovaline. In other aspects, AA is lanthionine. In further aspects, AA is N-ethylalanine. In still other aspects, AA is N-ethylglycine. In still further aspects, AA is N-ethyl beta-alanine. In other aspects, AA is N-isopropylglycine. In further aspects, AA is N-methylalanine. In yet other aspects, AA is N-methyl beta-alanine. In yet further aspects, AA is norleucine. In other aspects, AA is norvaline. In further aspects, AA is N-propylglycine. In still other aspects, AA is O-methyl-homoserine. In still further aspects, AA is ornithine. In other aspects, AA is pipecolic acid. In further aspects, AA is pyroglutamic acid. In still other aspects, AA is sarcosine.In further aspects, AA is selenocysteine. In other aspects, AA is selenohomocysteine. In further aspects, AA is selenomethionine. In still other aspects, AA is selenoethionine. In further aspects, AA is taurine. In other aspects, AA is tert-leucine. In further aspects, AA is α,β-diaminopropionic acid. In still other aspects, AA is α,γ-diaminobutyric acid. In further aspects, AA is α-aminoisobutyric acid. In other aspects, AA is α-amino-n-butyric acid. In further aspects, AA is α-amino-n-heptanoic acid. In still other aspects, AA is α-hydroxy-γ-aminobutyric acid. In further aspects, AA is β-alanine. In other aspects, AA is β-aminoisobutyric acid. In further aspects, AA is β-amino-n-butyric acid. In still other aspects, AA is γ-aminobutyric acid. In further aspects, AA is δ-aminolevulinic acid. In other aspects, AA is 1-aminocyclopropane-1-carboxylic acid. In further aspects, AA is azetidine-2-carboxylic acid. In still other aspects, AA is cycloleucine. In yet further aspects, AA is pseudoproline. The amino acid is attached to R. 4 The amino acid can be bound to the oxygen atom at any position of the amino acid backbone. For example, in some embodiments, the amino acid is connected to the oxygen atom via the carbonyl group of the amino acid.
[0131] In these structures, R 5 The resin is a resin. A resin suitable for use herein can be selected by a person skilled in the art. In some embodiments, the resin comprises a carboxyl group. Ideally, the resin comprises a cleavable group. The term "cleavable group" as used herein refers to a group displaced from a compound of formula VC. In particular, the cleavable group is displaced from a compound of formula VC so that AA can be connected. In some embodiments, the cleavable group is OH or a carboxyl group. In other embodiments, the cleavable group is OH. In further embodiments, the cleavable group is a carboxyl group. In yet other embodiments, the cleavable group is a polystyrene resin.
[0132] The activating agent utilized can be selected by one skilled in the art.
[0133] In some aspects, the activating agent is 1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU), 1H-1,2,3-benzotriazol-1-yloxy-tris(pyrrolidinyl)- Hexafluorophosphate (PyBOP), 1-hydroxy-7-azabenzotriazole (HOAt), 2-(1H-7-azabenzotriazol-1-yl)-1,1,3-tetramethyluronium hexafluorophosphate (HATU), benzotriazol-1-yl-oxy-tris(dimethylamino) Hexafluorophosphate (BOP), chloro-N,N,N',N'-tetramethylformamidine hexafluorophosphate, dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), ethyl cyano(hydroxyimino)acetate-O 2 ]Tri-1-pyrrolidinyl Hexafluorophosphate (ethylcyano(hydroxyimino)acetato-O 2 ]tri-1-pyrrolidinylphosphoniumhexafluorophosphate, PyOxim), cyanohydroxyiminoethyl acetate (Oxyma), N,N'-diisopropylcarbodiimide (DIC), N-hydroxybenzotriazole (HOBT), O-(1H-benzotriazole-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), O-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) or O-benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), or a combination thereof. In some aspects, the activator is COMU. In other aspects, the activator is PyBOP. In further aspects, the activator is HOAt. In still other aspects, the activator is HATU. In still further aspects, the activator is BOP. In other aspects, the activator is chloro-N,N,N',N'-tetramethylformamidine hexafluorophosphate. In further aspects, the activator is DCC. In still other aspects, the activator is DIC. In still further aspects, the activator is PyOxim. In other aspects, the activator is Oxyma. In further aspects, the activator is DIC. In still other aspects, the activator is HOBT. In still further aspects, the activator is TBTU. In other aspects, the activator is HCTU. In further aspects, the activator is HBTU.
[0134] The solvent used for this conversion can be selected by those skilled in the art. Preferably, the solvent is polar. Examples of solvents include NMP, DMF, DMSO, DCM or mixtures thereof. In some aspects, the solvent is NMP. In other aspects, the solvent is DMF. In further aspects, the solvent is DMSO. In yet other aspects, the solvent is DCM.
[0135] The intermediate is then contacted with a deprotecting agent for a period of time and under conditions effective to produce the compound of Formula VII:
[0136]
[0137] In some embodiments, the intermediate is converted to a compound of Formula VII-A, Formula VII-B, or Formula VII-C:
[0138]
[0139] In some embodiments, the intermediate is converted to a compound of Formula VII-A. In other embodiments, the intermediate is converted to a compound of Formula VII-B. In further embodiments, the intermediate is converted to a compound of Formula VII-C.
[0140] Those skilled in the art will be able to select a suitable deprotecting agent. In some embodiments, the deprotecting agent is a base. Examples of bases include piperidine, 4-methylpiperidine, piperazine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or morpholine, or a combination thereof without limitation. In certain aspects, the base is piperidine. In other aspects, the base is 4-methylpiperidine. In further aspects, the base is piperazine. In yet other aspects, the base is DBU. In a further aspect, the base is morpholine.
[0141] The compound of formula VII is then converted to a compound of formula VIIIA, formula VIII-B or formula VIII-C:
[0142]
[0143] In some embodiments, the compound of formula VII-A is converted to a compound of formula VIII-A. In other embodiments, the compound of formula VII-B is converted to a compound of formula VIII-B. In further embodiments, the compound of formula VII-C is converted to a compound of formula VIII-C.
[0144] Such transformations are carried out by contacting a compound of Formula VII with a compound of Formula II in the presence of an activating agent as described above. Thereafter, the reaction is contacted with a deprotecting agent as described above for a period of time and under conditions effective to produce a compound of Formula VIII-A, Formula VIII-B or Formula VIII-C.
[0145] Advantageously, the compound of formula VIII-A, formula VIII-B or formula VIII-C can be further reacted with a compound of formula II to provide a corresponding larger compound, for example a compound of formula XV-A, formula XV-B or formula XV-C:
[0146]
[0147] In other embodiments, compounds of XV-A can be prepared. In further embodiments, compounds of XV-B can be prepared. In still other embodiments, compounds of XV-C can be prepared.
[0148] As a general rule, these larger compounds are formed by reacting the product of each reaction involving a compound of formula II with another compound of formula II. The number of times ("w" times) the reaction with the compound of formula II is carried out is determined by the size of the desired compound. In certain embodiments, the product is reacted with the compound of formula II 1 to 20 times (i.e., w is an integer from 1 to 20). In other embodiments, w is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. In further embodiments, w is an integer from 2 to 18, 2 to 16, 2 to 14, 2 to 12, 2 to 10, 2 to 8, 2 to 6, 2 to 4, 4 to 20, 4 to 18, 4 to 16, 4 to 14, 4 to 12, 4 to 10, 4 to 8, 4 to 6, 6 to 20, 6 to 18, 6 to 16, 6 to 14, 6 to 12, 6 to 10, 6 to 8, 8 to 20, 8 to 18, 8 to 16, 8 to 14, 8 to 12, 8 to 10, 10 to 20, 10 to 18, 10 to 16, 10 to 14, 10 to 12, 12 to 20, 12 to 18, 12 to 16, 12 to 14, 14 to 20, 14 to 18, 14 to 16, 16 to 20, 16 to 18, or 18 to 20. In yet other embodiments, w is an integer from 1 to 8. In still further embodiments, w is from 6 to 8.
[0149] The compound of formula VIII-A, formula VIII-B or formula VIII-C can then be converted to a compound of formula IX-B, formula IX-B or formula IX-C:
[0150]
[0151] In some embodiments, a compound of formula XIII-A is converted to a compound of formula IX-A. In other embodiments, a compound of formula VIII-B is converted to a compound of formula IX-B. In further embodiments, a compound of formula VIII-C is converted to a compound of formula IX-C. Such conversion is performed by contacting a compound of formula VIII-A, formula VIII-B or formula VIII-C with a compound of formula II in the presence of an activating agent as described above. Thereafter, the reaction is contacted with a deprotecting agent as described above for a period of time under conditions effective to produce a compound of formula IX-A, formula IX-B or formula IX-C.
[0152] The compound of formula IX-A, formula IX-B or formula IX-C can then be converted to a compound of formula XB, formula XB or formula XC:
[0153]
[0154] In some embodiments, the compound of formula IX-A is converted to a compound of formula XA. In other embodiments, the compound of formula XIII-A is converted to a compound of formula XB. In further embodiments, the compound of formula XIII-A is converted to a compound of formula XC.
[0155] Such transformations are carried out by contacting a compound of Formula IX-A, Formula IX-B or Formula IX-C with a compound of Formula II in the presence of an activating agent as described above. Thereafter, the reaction is contacted with a deprotecting agent as described above under conditions effective to produce a compound of Formula XA, Formula XB or Formula XC for a period of time.
[0156] The compound of formula XA, formula XB or formula XC can then be converted to a compound of formula XI-B, formula XI-B or formula XI-C:
[0157]
[0158] In some embodiments, the compound of formula XA is converted to a compound of formula XI-A. In other embodiments, the compound of formula XB is converted to a compound of formula XI-B. In further embodiments, the compound of formula XC is converted to a compound of formula XI-C.
[0159] The compound of formula XA, formula XB or formula XC is converted into a compound of formula XI-A, formula XI-B or formula XI-C by reaction with an activator as described herein and YZ. Y is defined as an aminocarbonyl group and Z is a leaving group. The term "aminocarbonyl" as used herein refers to any chemical functional group comprising NH2 and a C(O) group. Y is H or an amino acid. In some aspects, Y is H. In other aspects, Y is an amino acid. Examples of amino acids include those described herein. Amino acids can be selected by those skilled in the art. In some aspects, Y is a natural amino acid or a non-natural amino acid. In some aspects, Y is Arg, His, Lys, Asp, Glu, Ser, Thr, Asn, Gln, Cys, Sec, Gly, Pro, Ala, Val, Ile, Leu, Met, Phe, Tyr, Trp or pyrrolysine. In some aspects, Y is Gly. In other aspects, Y is Ala. In further aspects, Y is Val. In still other aspects, Y is Leu. In further aspects, Y is Ile. In other aspects, Y is Pro. In further aspects, Y is Ser. In still other aspects, Y is Thr. In further aspects, Y is Asp. In other aspects, Y is Gln. In further aspects, Y is Cys. In other aspects, Y is Met. In further aspects, Y is Phe. In other aspects, Y is Tyr. In further aspects, Y is Trp. In still other aspects, Y is Asp. In further aspects, Y is Glu. In other aspects, Y is His. In further aspects, Y is Lys. In still other aspects, Y is Arg. In further aspects, Y is selenocysteine. In other aspects, Y is pyrrolysine. In further aspects, Y is β-alanine.
[0160] Y can also be selected from unnatural amino acids, such as PABA, alloisoleucine, allothreonine, carboxyglutamic acid, cystathionine, D-alanine, dehydroalanine, D-glutamic acid, diaminopimelic acid, leucine, glycine betaine, homocysteine, homonorleucine, homoserine, hydroxyglycine, hydroxyproline, hydroxyputrescine lysine, isoserine, isovaline, lanthionine, N-ethylalanine, N-ethylglycine, N-ethylβ-alanine, N-isopropylglycine, N-methylalanine, N-methylβ-alanine, norleucine, norvaline, N-propylglycine In some aspects, Y is PABA. In other aspects, Y is allo-isoleucine. In further aspects, Y is allo-threonine. In yet other aspects, Y is carboxyglutamic acid. In further aspects, Y is cystathionine. In other aspects, Y is D-alanine. In further aspects, Y is dehydroalanine. In still other aspects, Y is D-glutamic acid. In still further aspects, Y is diaminopimelic acid. In still further aspects, Y is leucine. In other aspects, Y is glycine betaine homocysteine. In further aspects, Y is homonorleucine. In still other aspects, Y is homoserine. In still further aspects, Y is hydroxyglycine. In other aspects, Y is hydroxyproline. In further aspects, Y is hydroxyputrescine lysine. In still other aspects, Y is isoserine. In still further aspects, Y is isovaline. In other aspects, Y is lanthionine. In further aspects, Y is N-ethylalanine. In still other aspects, Y is N-ethylglycine. In still further aspects, Y is N-ethyl beta-alanine. In other aspects, Y is N-isopropylglycine. In further aspects, Y is N-methylalanine. In yet other aspects, Y is N-methyl beta-alanine. In yet further aspects, Y is norleucine. In other aspects, Y is norvaline. In further aspects, Y is N-propylglycine. In still other aspects, Y is O-methyl-homoserine. In still further aspects, Y is ornithine. In other aspects, Y is pipecolic acid. In further aspects, Y is pyroglutamic acid. In still other aspects, Y is sarcosine. In still further aspects, Y is selenocysteine. In other aspects, Y is selenohomocysteine.In a further aspect, Y is selenomethionine. In yet other aspects, Y is selenoethionine. In yet further aspects, Y is taurine. In other aspects, Y is tert-leucine. In further aspects, Y is α,β-diaminopropionic acid. In yet other aspects, Y is α,γ-diaminobutyric acid. In yet further aspects, Y is α-aminoisobutyric acid. In other aspects, Y is α-amino-n-butyric acid. In further aspects, Y is α-amino-n-heptanoic acid. In yet other aspects, Y is α-hydroxy-γ-aminobutyric acid. In yet further aspects, Y is β-alanine. In other aspects, Y is β-aminoisobutyric acid. In further aspects, Y is β-amino-n-butyric acid. In yet other aspects, Y is γ-aminobutyric acid. In yet further aspects, Y is δ-aminolevulinic acid. In other aspects, Y is 1-aminocyclopropane-1-carboxylic acid. In a further aspect, Y is azetidine-2-carboxylic acid. In yet other aspects, Y is cycloleucine. In yet further aspects, Y is pseudoproline.
[0161] Thereafter, a deprotecting agent as described above is added for a period of time and under conditions effective to produce a compound of Formula XI-A, Formula XI-B, or Formula XI-C, respectively.
[0162] Z is a leaving group, which can be selected by those skilled in the art. In some embodiments, Z is a halogen, a sulfonate, an N-hydroxybenzotriazolyl group, a 1-hydroxy-7-azabenzotriazolyl group, or In other embodiments, Z is a halogen, such as chlorine, fluorine, or bromine. In further embodiments, Z is a sulfonate, such as p-toluenesulfonate (OTs), methanesulfonate (OMs), or trifluoromethanesulfonate (OTf). In still other embodiments, Z is N-hydroxybenzotriazolyl. In further embodiments, Z is 1-hydroxy-7-azabenzotriazolyl. In other embodiments, Z is
[0163] The compound of Formula XI-A can then be contacted with a weak acid for a period of time and under conditions sufficient to produce the compound of Formula XII-A:
[0164]
[0165] In some embodiments, a compound of Formula XII-A is produced.
[0166] The weak acid utilized in the conversion can be selected by those skilled in the art. In some embodiments, the weak acid is trifluoroacetic acid or acetic acid. In other embodiments, the weak acid is trifluoroacetic acid. In further embodiments, the weak acid is acetic acid.
[0167] In some embodiments, the pH of the weak acid is between about 1 and about 7. In some embodiments, the pH of the weak acid is between about 2 and about 6. In some embodiments, the pH of the weak acid is between about 2 and about 5. In some embodiments, the pH of the weak acid is between about 3 and about 4. In one embodiment, the pH of the weak acid is about 7. In one embodiment, the pH of the weak acid is about 6. In one embodiment, the pH of the weak acid is about 5. In one embodiment, the pH of the weak acid is about 4. In one embodiment, the pH of the weak acid is about 3. In one embodiment, the pH of the weak acid is about 2. In one embodiment, the pH of the weak acid is about 1.
[0168] In some embodiments, the concentration of the weak acid is about 50 to about 200 mM. In further embodiments, the concentration of the weak acid is about 50 mM, about 75 mM, about 100 mM, about 125 mM, about 150 mM, about 175 mM, or about 200 mM. In other embodiments, the concentration of the weak acid is about 50 to about 175 mM, about 50 to about 150 mM, about 50 to about 125 mM, about 50 to about 100 mM, about 50 to about 75 mM, about 75 to about 200 mM, about 75 to about 175 mM, about 75 to about 150 mM, about 75 to about 125 mM, about 75 to about 100 mM, about 100 to about 200 mM, about 100 to about 175 mM, about 100 to about 150 mM, about 100 to about 125 mM, about 125 to about 200 mM, about 125 to about 175 mM, about 125 to about 150 mM, about 150 to about 200 mM, about 150 to about 175 mM, or about 175 to about 200 mM. In further embodiments, the weak acid is about 50 to about 200 mM acetic acid.
[0169] The weak acid may contain a solvent. Examples of such solvents include, but are not limited to, methanol, ethanol, isopropanol and / or butanol, and / or polar aprotic solvents such as dimethylformamide, N-methylpyrrolidone, and the like.
[0170] The amount of time required to prepare the spirocyclic compounds described herein (including compounds of Formula XII-A) is from about 1 minute to about 24 hours, preferably from about 2 to about 12 hours. In some embodiments, the time is about 1 minute, about 5 minutes, about 15 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours. In other embodiments, the time is from about 1 minute to about 18 hours, from about 1 minute to about 12 hours, from about 1 minute to about 8 hours, from about 1 minute to about 4 hours, from about 1 minute to about 1 hour, from about 1 minute to about 30 minutes, from about 30 minutes to about 24 hours, from about 30 minutes to about 18 hours, from about 30 minutes to about 12 hours, from about 30 minutes to about 8 hours, from about 30 minutes to about 4 hours, from about 30 minutes to about 1 hour, from about 1 hour to about 24 hours, from about 1 hour to about 18 hours, from about 1 hour to about 12 hours, from about 1 hour to about 8 hours, from about 1 hour to about 4 hours, from about 4 hours to about 24 hours, from about 4 hours to about 18 hours, from about 4 hours to about 12 hours, from about 4 hours to about 8 hours, from about 8 hours to about 24 hours, from about 8 hours to about 18 hours, from about 8 hours to about 12 hours, from about 12 hours to about 24 hours, from about 12 hours to about 18 hours, or from about 18 to about 24 hours.
[0171] The temperature used to prepare the compound of Formula XII-A is from about room temperature to elevated temperature. The term "room temperature" as used herein refers to a temperature of about 30°C to about 35°C. In some embodiments, the temperature is about 30 to about 60°C. In other embodiments, the temperature is about 30°C, about 35°C, about 40°C, about 45°C, about 50°C, about 55°C, or about 60°C. In further embodiments, the temperature is from about 30°C to about 55°C, from about 30°C to about 50°C, from about 30°C to about 45°C, from about 30°C to about 40°C, from about 30°C to about 35°C, from about 35°C to about 60°C, from about 35°C to about 55°C, from about 35°C to about 50°C, from about 35°C to about 45°C, from about 35°C to about 40°C, from about 40°C to about 60°C, from about 40°C to about 55°C, from about 40°C to about 50°C, from about 40°C to about 45°C, from about 45°C to about 60°C, from about 45°C to about 55°C, from about 45°C to about 50°C, from about 50°C to about 60°C, from about 50°C to about 55°C, or from about 55°C to about 60°C.
[0172] The present invention further provides a process for preparing compounds of formula XV:
[0173]
[0174] In the structure of Formula XV, R 1 , R 2 , R 4 , x is as defined herein. w is an integer from 1 to 20. In some embodiments, w is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In other embodiments, w is from 1 to 18, 1 to 16, 1 to 14, 1 to 12, 1 to 10, 1 to 8, 1 to 6, 1 to 4, 1 to 2, 2 to 20, 2 to 18, 2 to 16, 2 to 14, 2 to 12, 2 to 10, 2 to 8, 2 to 6, 2 to 4, 4 to 20, 4 to 18, 4 to 16, 4 to 14, 4 to 12, 4 to 10, 4 to 8, 4 to 6, 6 to 20, 6 to 18, 6 to 1 In some embodiments, y is an integer from 0 to 1 or 1. In some embodiments, y is an integer from 0 to 1 or 1. In some embodiments, y is an integer from 0 to 1 or 1. In some embodiments, y is an integer from 0 to 1 or 1. In some embodiments, y is an integer from 0 to 1 or 1. In some embodiments, y is an integer from 0 to 1 or 1. In some embodiments, y is an integer from 0 to 1 or 1. In some embodiments, y is an integer from 0 to 1 or 1.
[0175] The method for preparing a compound of formula XV comprises a compound of formula II and a compound of formula VI, wherein x, z, R 1 , R 2 , R 5 and AA is as defined herein:
[0176]
[0177] The method is carried out using an activating agent as defined herein and a base as defined herein to provide an intermediate. The intermediate is then contacted with a deprotecting agent as defined herein for a period of time under conditions effective to produce a compound of formula VII:
[0178]
[0179] Then the compound of formula VII is contacted with the compound of formula II (w-1) times, wherein w is defined in this article. As used herein, the term "w-1" times means that the compound of formula VII is contacted with the compound of formula II to provide the first intermediate. Then the first intermediate is contacted with the compound of formula II to provide the second intermediate, etc. In some embodiments, the compound of formula VII is contacted with the compound of formula II 1-19 times. In some embodiments, the compound of formula VII is contacted with the compound of formula II 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 times. In other embodiments, the compound of Formula VII is contacted with a compound of Formula II and w is 1 to 18, 1 to 16, 1 to 14, 1 to 12, 1 to 10, 1 to 8, 1 to 6, 1 to 4, 1 to 2, 2 to 20, 2 to 18, 2 to 16, 2 to 14, 2 to 12, 2 to 10, 2 to 8, 2 to 6, 2 to 4, 4 to 20, 4 to 18, 4 to 16, 4 to 14, 4 to 12, 4 to 10, 4 to 8, 4 to 6, 6 to 2 or an integer from 0, 6 to 18, 6 to 16, 6 to 14, 6 to 12, 6 to 10, 6 to 8, 8 to 20, 8 to 18, 8 to 16, 8 to 14, 8 to 12, 8 to 10, 10 to 20, 10 to 18, 10 to 16, 10 to 14, 10 to 12, 12 to 20, 12 to 18, 12 to 16, 12 to 14, 14 to 20, 14 to 18, 14 to 16, 16 to 20, 16 to 18, or 18 to 20 times.
[0180] The present invention also provides a process for preparing a compound of formula I, wherein x, z and R 4 As defined in this article:
[0181]
[0182] The method comprises contacting a compound of formula III, wherein M is a transition metal having a +2 oxidation state as defined herein:
[0183]
[0184] The process is carried out using a chelating agent as defined herein and under conditions and for a time effective to produce a compound of formula I.
[0185] The present invention further provides a process for preparing a compound of formula III, wherein X, Z and R 4 As defined in this article:
[0186]
[0187] The method comprises contacting a compound of formula IV with 9-fluorenylmethoxyphosgene for a period of time and under conditions effective to produce a compound of formula III.
[0188] The present invention further provides a process for preparing a compound of formula IV, wherein x, z and R 4 As defined in this article:
[0189]
[0190] The method comprises contacting a compound of formula V with a source of metal (II) as defined herein:
[0191]
[0192] The process is carried out for a period of time and under conditions effective to produce the compound of formula IV.
[0193] The present invention also provides a method for preparing a compound of formula VII, wherein x, y, z, R 4 , R 5 and AA is as defined herein:
[0194]
[0195] The method comprises contacting a compound of formula II with a compound of formula VI:
[0196]
[0197] The process is carried out using an activating agent as defined herein and a base as defined herein to provide an intermediate, and contacting the intermediate with a deprotecting agent as defined herein for a time and under conditions effective to produce a compound of formula VII.
[0198] Compound
[0199] Advantageously, the methods described herein allow for the preparation of an unlimited number of compounds. In certain embodiments, the present invention provides compounds of Formula XIV:
[0200]
[0201] In this structure, R 1 , R 2 Each instance of , x, y, and z is independently defined herein.
[0202] Also provided is a compound of formula II or a salt thereof, wherein y, R 1 , R 2 and R 4 As defined in this article:
[0203]
[0204] The present invention also provides compounds of formula II-A, formula II-B or formula II-C, wherein R 1 and R 4 As defined in this article:
[0205]
[0206] In some embodiments, the compound is a compound of formula II-A. In other embodiments, the compound is a compound of formula II-B. In further embodiments, the compound is a compound of formula II-C.
[0207] In yet other embodiments, the compound is:
[0208]
[0209]
[0210]
[0211] In a further compound, the present invention provides a compound, which is:
[0212]
[0213] The present invention further provides a compound, which is:
[0214]
[0215] The present invention also provides a compound, which is:
[0216]
[0217] It should be understood that, although the present invention has been described in conjunction with preferred specific embodiments of the present invention, the foregoing description and subsequent examples are intended to illustrate and do not limit the scope of the present invention. It will be appreciated by those skilled in the art that, without departing from the scope of the present invention, various changes may be made and equivalents may be substituted, and further, other aspects, advantages and modifications will be apparent to those skilled in the art to which the present invention belongs. In addition to the embodiments described herein, the present invention contemplates and requests protection for those inventions derived from the combination of the features of the present invention cited herein with the features of the cited prior art references that supplement the features of the present invention.
[0218] The present invention of each patent, patent application, and publication cited or described in this document is each hereby incorporated by reference in its entirety for all purposes.
[0219] Experimental example
[0220] The present invention is further described in detail by reference to the following experimental examples. These embodiments are provided for illustrative purposes only, and unless otherwise indicated, are not intended to be limiting. Therefore, the present invention should never be interpreted as being limited to the following examples, but should be interpreted as covering any and all changes that become apparent due to the teachings provided herein.
[0221] Without further description, it is believed that one of ordinary skill in the art can use the foregoing description and the following illustrative examples to make and utilize the present invention and practice the claimed methods. Therefore, the following examples specifically point out preferred embodiments of the present invention and should not be construed as limiting the remainder of the disclosure in any way.
[0222] Example 1: Development of Fmoc-protected diamino acids to automated synthesis of highly functionalized spirocyclic oligomers
[0223] "Molecular structure determines function"-this is the most basic paradigm of molecular biology (Gutteridge, A. et al., Trends in Biochemical Sciences 2005, 30 (11), 622-629). The goal of macromolecular chemistry is to create larger and larger molecules, control their three-dimensional structures and the series of combinations (constellation) of functional groups they present (Lenci, E. et al., Chemical Society Reviews 2020, 49 (11), 3262-3277; Lutz, J.-F et al., Science 2013, 341 (6146), 1238149). Stoddart first introduced the concept of "molecular LEGO", which can be designed to have the desired shape by iterative ring fusion, such as with [n] aromatics and kohnkenes (Hill, DJ et al., Chemical Reviews 2001, 101 (12), 3893-4012). More recently, the Bode group demonstrated the iterative assembly of polycyclic saturated heterocyclic compounds from monomer building blocks (Saito, F et al., Journal of the American Chemical Society 2019, 141(13), 5544-5554).
[0224] Spiro oligomers are fused-ring spiral ladder structures composed of cyclic stereochemically pure diamino acid building blocks connected together by diketopiperazine (DKP) rings (Schafmeister, CE et al., Accounts of Chemical Research 2008, 41 (10), 1387-1398). The formation of spirocyclic DKPs enhances the rigidity of the skeleton by eliminating single-bond rotations in the skeleton. At the same time, the positions and orientations of the various functional groups on the skeleton are determined by the order and stereochemistry of the building blocks. Spirocyclic oligomers are being developed for a variety of applications, including as catalysts for organic reactions (Parker, MFL et al., Journal of the American Chemical Society 2014, 136(10), 3817-3827), templates for supramolecular metal-binding complexes (Northrup, JD et al., Journal of Organic Chemistry 2021, 86(6), 4867-4876), inhibitors of protein-protein interactions (Brown, ZZ et al., Plos One 2012, 7(10)), and carbohydrate-binding molecules (Chepyshev, SV et al., Rocky Mountain Regional Meeting, Fort Collins, CO, United States 2020).
[0225] Functionalized spirocyclic oligomer synthesis has always been difficult because, even at a scale of ~600 mmol, monomer synthesis is time-consuming. Previously, original carboxybenzyl (Cbz), tert-butyloxycarbonyl (Boc) and p-nitrobenzyloxycarbonyl (pNZ) have been used as chain-extending removable protecting groups for proline amine in solid phase synthesis. These protecting groups are difficult to remove (e.g., Cbz) or cause side reactions during deprotection and limit the choice of resin attachment groups to those that provide low yields (Cheong, JE, Tetrahedron Letters 2016, 57 (44), 4882-4884; Pfeiffer, CT et al., Tetrahedron Letters 2018, 59 (30), 2884-2888).
[0226] The fluorenylmethoxycarbonyl (Fmoc) group as an excellent temporary protecting group in peptide synthesis allows the use of excellent high-yield cleavable resin linking groups, such as chloro-trityl linking groups (Behrendt, R. et al., Journal of Peptide Science 2016, 22 (1), 4-27; Ieronymaki, M. et al., Biopolymers 2015, 104 (5), 506-514; Stathopoulos, P. et al., Journal of Peptide Science 2006, 12 (3), 227-232). The research described herein efficiently introduces the Fmoc group into the synthesis of spirocyclic oligomers. The method combines the amplified synthesis of double amino acid intermediates on a scale of tens of kilograms with an efficient one-pot synthesis method to replace the Cbz group with the Fmoc group. Four unique spirocyclic oligomers were synthesized using Fmoc / tBu solid phase synthesis, and their three-dimensional structures were confirmed by nuclear magnetic resonance (NMR) spectroscopy.
[0227] In order to significantly reduce the labor cost of diamino acid synthesis and take advantage of economies of scale, a large-scale synthesis of key ketone intermediates 2a and 2b was developed. Compared with the previous synthesis (Cheong, JE, Tetrahedron Letters 2016, 57(44), 4882-4884), the current approach has increased the scale of intermediate synthesis by three orders of magnitude ( Figure 2 ). The scaled-up synthesis eliminated the use of the highly toxic Jones reagent (Caron, S. et al., Chemical Reviews 2006, 106(7), 2943-2989), replacing it with a (2,2,6,6-tetramethylpiperidin-1-yl)oxy (TEMPO)-mediated trichloroisocyanuric acid (TCCA) oxidation that avoids downstream problems with impurities encountered at small scale.
[0228] The scaled-up synthesis also eliminated the explosive isobutylene gas that was a problem at the pilot plant scale (Wright, SW et al., Tetrahedron Letters 1997, 38(42), 7345-7348), and utilized the tert-butylating agent 2,2,2-trichloroacetimidate (TBTA) instead. In less than two months, tens of kilograms of stereochemically pure S- and R-enantiomers were produced at a cost of less than $4 per gram in a more environmentally friendly manner than previous syntheses.
[0229] According to a previously developed protocol (Cheong, JE, Tetrahedron Letters 2016, 57 (44), 4882-4884), the Bucherer-Bergs reaction converts 2a and 2b into a mixture of diastereomeric hydantoins, wherein, for 2a, the ratio of the (2S, 4S) stereoisomer to the (2S, 4R) stereoisomer is approximately 5: 1. Using a large-scale flash chromatography system, a dichloromethane / isopropanol gradient is used to separate ~200 g of crude hydantoin diastereomers in one load. A solvent recovery system is used to recover the dichloromethane. Each separated stereochemically pure hydantoin product is then hydrolyzed to give four optically pure diamino acids (3a-d) as previously reported (Cheong, JE, Tetrahedron Letters 2016, 57 (44), 4882-4884). The detailed multi-kilogram scale synthesis is described below.
[0230] Since the Fmoc group is sensitive to bases, Fmoc protection of the building block needs to be performed after hydrolysis of hydantoin and removal of the Cbz group. Inspired by the selective ω-amino protection of lysine (Malkar, NB et al., Letters in Peptide Science 2000, 7 (5), 263-267), an efficient synthesis of the installation of the Fmoc group on the proline nitrogen was developed. This relies on the formation of a dimeric Cu(II) complex containing two carboxylic acids and two α-amino groups that temporarily blocks the primary amino group. The carboxylic acid at C2 is protected by a tert-butyl group, which prevents it from forming a complex with copper together with the amine at C1. Therefore, the free primary amine and carboxylic acid at C4 are protected by reacting with Cu 2+ The copper complex is blocked by complexation. The proline nitrogen in the building block is then protected with an Fmoc protecting agent such as Fmoc-Cl or Fmoc-OSu. The copper complex is then dissociated by a strong chelating agent in the final stage of the exchange. This strategy was applied to four diamino acid stereoisomers (3a-d; Figure 3 ).
[0231] Cbz deprotection was performed by hydrogenolysis with Pd / C in aqueous Na2CO3 solution. The product was used without purification in the following Cu(II) complexation step. Half an equivalent of CuCl2 was added directly to the suspension to form a complex with the free amine and carboxylic acid at the C4 position of the diamino acid, providing a dark blue solution mixed with Pd / C powder. Under Schotten-Baumann reaction conditions, a slight excess of Fmoc-Cl in EtOAc was added dropwise to the aqueous slurry. The biphasic mixture was vigorously stirred for 2 hours before the Pd / C was filtered out using a short diatomaceous earth plug. The top EtOAc layer turned blue with a much higher intensity than the aqueous phase below, indicating that an Fmoc-protected Cu complex was formed, which was present in the organic phase due to reduced polarity. Impurities in the aqueous phase were removed by a separatory funnel. The collected organic phase was stirred with an aqueous solution of ethylenediaminetetraacetic acid (EDTA) to remove Cu 2+ .
[0232] After 12 hours, the blue color completely transferred from the organic phase to the aqueous phase, indicating that Cu 2+ Once the Fmoc-protected bis-amino acid building blocks 4a-d were released from the copper complex, they precipitated from the biphasic system to form white crystalline powders, such as Fig.25 The pure mono-protected solid products 4a-d were then isolated by vacuum filtration, while a small amount of unreacted starting material and impurities remained in the pale yellow EtOAc phase and the Cu-EDTA byproduct remained in the blue aqueous phase. This four-step process does not involve chromatography.
[0233] Prior to solid phase assembly, various functional groups were introduced into the building blocks using reductive alkylation by treating the building blocks with the corresponding aldehydes and the mild reducing agent NaBH3CN. This is an advantageous feature of spiro oligomer synthesis when functional groups selected from a large number of aldehydes can be installed in stereochemically pure building blocks to form measurable amounts of individual monomers for solid phase synthesis of spiro oligomers. Each Fmoc diamino acid diastereomer was alkylated with a different functional group to obtain functionalized building blocks 5a-d ( Figure 4 ).
[0234] Four side chains were chosen to represent a wide range of functionalities, including alkyl, fused aromatic, heterocyclic, and aryl halide groups. For functionalization of the Fmoc building block and activation of the Pfp ester, methods previously used for pNZ, Boc, and Cbz building blocks were found to be compatible with the new Fmoc building block (Pfeiffer, CT et al., Tetrahedron Letters 2018, 59(30), 2884-2888; Brown, ZZ et al., Biopolymers 2011, 96(5), 578-585).
[0235] By adding DCM and methanol in a 1:1 ratio, the (2S,4R)- and (2R,4S)-diastereomers were dissolved to improve the efficiency of the reductive alkylation. Solid loading of the crude slurry onto celite with the aid of large amounts of methanol and normal phase chromatography purification of the functionalized bis-amino acids under a 0-20% methanol gradient in DCM was found to be highly efficient with yields ranging from 61% to 90%.
[0236] Consistent with previous findings, the functionalized secondary amines at the quaternary centers of the building blocks are sterically hindered to prevent them from coupling with activated esters at any appreciable rate (Brown, ZZ et al., Journal of the American Chemical Society 2008, 130(44), 14382-14383). Therefore, they can be used as monomers for solid phase synthesis without protecting the secondary amines on 5a-d.
[0237] Dimerization of building blocks using traditional in situ activated coupling strategies was previously observed (Brown, ZZ et al., Journal of the American Chemical Society 2008, 130(44), 14382-14383). Figure 4 As shown in, pentafluorophenol (Pfp-OH) was used to pre-activate the monomers and obtain bench-stable building blocks 6a-d to minimize dimerization (Pfeiffer, CT et al., Tetrahedron Letters 2018, 59(30), 2884-2888). In the coupling step, the Pfp ester of the building block can be added directly to the amine on the solid support to avoid the formation of symmetrical dimers. Each monomer was purified by normal phase column chromatography with 0-50% hexane / EtOAc and stored at -20°C until needed.
[0238] Highly functionalized spirocyclic oligomers were assembled by solid phase synthesis using four stereoisomers of building blocks 6a-d on a semi-automated microwave peptide synthesizer. Figure 6 As shown in , L-proline was first loaded onto 2-chlorotrityl chloride resin using N,N-diisopropylethylamine (DIPEA), followed by deprotection of the Fmoc group to produce 7. The second residue, Pfp ester 6a, was coupled using a similar HOAt / DIPEA protocol developed for the pNZ building block (Pfeiffer, CT et al., Tetrahedron Letters 2018, 59(30), 2884-2888).
[0239] After optimization, it was found that 2 equivalents of building blocks were sufficient to complete the coupling in 1 hour at 50°C in the presence of 4 equivalents of HOAt and 8 equivalents of DIPEA. Excess base was used to balance the acidity of the excess HOAt, which prematurely cleaved the extremely sensitive chloro-trityl linking group. The Fmoc was removed after coupling building block 6b to the resin to obtain 9. The Fmoc group was removed after coupling of the next diamino acid 6c to obtain 10. This method was repeated for the installation of the last building block 6d to form compound 11. The sequence was capped by Fmoc-Dab(Boc)-OH to provide 12, which was released from the solid phase by exposure to TFA. After heating the TFA solution containing the cleavage product 12 at 40°C overnight, the DKP in the tetramer T1 was completely formed, presumably by acid-catalyzed condensation. No obvious by-products were observed in the crude HPLC ( Fig.26 The final yield of T1 after preparative HPLC was 30% based on the maximum loading of the resin.
[0240] To demonstrate the versatility of this synthetic approach, three other tetramers T2-T4 ( Figure 5 The composition of T1-T4 was verified by high-resolution mass spectrometry (QTOF MS). Figures 27 to 30 ). Two-dimensional NMR experiments: Double quantum filter correlation spectroscopy (DQF-COSY), heteronuclear single quantum coherence spectroscopy (HSQC), heteronuclear multiple bond correlation spectroscopy (HMBC) and heteronuclear multiple quantum coherence (HMQC) were performed in DMSO-d6 and used to assign 1 H and 13 C resonances. The expected connectivity was confirmed by cross peaks from correlations between adjacent building blocks in the band selective HMBC spectra. Rotating frame Overhauser effect spectroscopy (ROESY) correlations were used to identify the relative stereochemistry of the C2 hydrogen and C4 hydrogen in each pyrrolidine and to confirm their configuration relative to the configuration of the C1 carbon on each building block.
[0241] Furthermore, all side chains have hydrogens that show ROESY correlations with backbone hydrogens, and they are consistent with side chains having a preferred orientation. Figure 6 As shown in Figure 1, one of the beta protons FHB2, which is below the plane of the second diamino acid proline ring, has a strong ROESY correlation with one of the methylene protons in the side group of the adjacent building block, GHa1 (solid red box). On the other hand, no correlation was found between GHa1-FHB1, GHa2-FHB1, or GHa2-FHB2 (expected at the location where the blue dashed circle was drawn, Figure 6 ). This indicates that the rotation of the side chains is restricted by interactions with the rigid backbone, as expected for a well-defined 3D structure. The energy-minimized structure of T1 is also Figure 5 Shown in.
[0242] In conclusion, this study demonstrates the scale-up of the synthesis of diamino acid intermediates to tens of kilograms. 2+ The complexation strategy was successfully used to selectively introduce the Fmoc group in a four-step one-pot process without chromatography with excellent yield and purity. Using these monomers, four spirocyclic oligomers were synthesized on a solid support with four different building blocks containing unique functional groups and stereochemistry. This work lays the foundation for the reliable and automated assembly of a library of highly functionalized spirocyclic oligomers.
[0243] In conclusion, this study describes the use of temporary Cu 2+ Fluorenylmethoxycarbonyl (Fmoc) protection of functionalized bis-amino acid building blocks by complexation strategy and efficient multi-kilogram-scale synthesis of bis-amino acid precursors. This allows the synthesis of stereochemically and functionally diverse spirocyclic oligomers using solid-phase Fmoc / tBu chemistry to facilitate the development of applications. Four tetramers were assembled on a semiautomated microwave peptide synthesizer. The secondary structure was also determined using two-dimensional nuclear magnetic resonance spectroscopy.
[0244] The materials and methods used in this experimental example are now described.
[0245] General process
[0246] Reactions were performed in standard and oven-dried glassware equipped with a PTFE-coated magnetic stirring bar. Stainless steel syringes were used to transfer air- and moisture-sensitive liquids. Reported concentrations refer to solution volumes at room temperature. Evaporation and concentration in vacuum were performed using a rotary evaporator.
[0247] Material
[0248] Unless otherwise stated, reagents were purchased from commercial suppliers at reagent grade and used without further purification.Compounds S2a, S3a, 2a, S2b, S3b and 2b were synthesized (Levins, CG et al., Journal of the American Chemical Society 2003, 125(16), 4702-4703). 1 The H NMR spectrum was very clean and compared well with published NMR spectra. Compounds 3a-d were synthesized following previously reported procedures (Cheong, JE et al., Tetrahedron Letters 2016, 57(44), 4882-4884).
[0249] instrument
[0250] Low-resolution high-performance liquid chromatography-mass spectrometry (LR-HPLC-MS)The analysis was performed on an Agilent 1290 HPLC system using Supelco An Express C8 column (2.7 μm packing, 2.1×50 mm) was used with a water-acetonitrile gradient solvent system containing 0.1% formic acid at a flow rate of 1.0 mL / min. The system was connected to an Agilent 6120 single quadrupole mass spectrometer using electrospray ionization.
[0251] High-resolution HPLC-MS The analysis was performed on an Agilent Infinity II series LCMS system with an Agilent Poroshell 120EC-C18 column (1.9 μm packing, 2.1×50 mm) using a water-acetonitrile gradient containing 0.1% formic acid at a flow rate of 1.0 mL / min. The system was connected to a 6000 series quadrupole time-of-flight (QTOF) mass spectrometer.
[0252] Preparative HPLC The analysis was performed on an Agilent Infinity II series LC / MSD system with a Phenomenex Aeris Peptide XB-C18 column (5 μm packing, 21.2×150 mm) using a water-acetonitrile gradient solvent system containing 0.1% trifluoroacetic acid at a flow rate of 25 mL / min with a single quadrupole mass spectrometer using electrospray ionization.
[0253] 1 H and 13 C one-dimensional nuclear magnetic resonance (NMR) Experiments were performed on a Bruker Avance 500 MHz instrument at 25°C. Chemical shifts are reported relative to the residual solvent peak or tetramethylsilane. Data are presented as follows: chemical shift, integral, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, qn = quintet, sp = septet, m = multiplet), coupling constants in Hertz (Hz). Some compounds exist as a mixture of two slowly interconverting rotamers at room temperature (on the NMR time scale) due to the tertiary amide. The rotamer peaks are indicated in the NMR data.
[0254] 2D NMR The experiments were performed on a Bruker Avance NEO 600 MHz spectrometer equipped with a cryoprobe at the Spectroscopy Support Facility (SSF) at Fox Chase Cancer Center.
[0255] Normal phase purification exist (Teledyne, Inc.) automated flash chromatography system using prepacked chromatograms of various sizes purchased from Sorbent Technologies. Rf silica gel column ( porosity, 230×400 mesh particle size).
[0256] Hydantoin diastereomers exist Isolera LS automated flash chromatography system SNAP KP-SIL 1500g column ( porosity, 50 μm particle size) separation.
[0257] Reverse phase purification Prepacked chromatographic plates of various sizes purchased from Sorbent Technologies were used on an ISCO (Teledyne, Inc.) automated flash chromatography system. Rf C18 reverse phase column ( Porosity, 230×400 mesh particle size) was performed using a water-acetonitrile gradient solvent system containing 0.1% formic acid.
[0258] Spiro oligomers Solid phase synthesis It was performed on a DiscoverBio semi-automatic microwave-assisted peptide synthesizer from CEM Corporation equipped with a 25 mL reaction vessel.
[0259] software
[0260] One-dimensional NMR spectra were processed with Bruker Topspin. Two-dimensional NMR spectra were analyzed with SPARKY (Goddard, TD; Kneller, DG Sparky 3.190; University of California: San Francisco, CA, 2015). (Lee, W. et al., Bioinformatics 2014, 31(8), 1325-1327).
[0261] Molecular images were generated using UCSF Chimera 1.14 (build 42094; Pettersen, EF et al., Journal of Computational Chemistry 2004, 25(13), 1605-1612).
[0262] The energy minimization of the three-dimensional structure of T1 was performed using the in-house software package CANDO (github.com / cando-developers / cando.git) using the generalized amber force field (GAFF) energy function (Wang, J. et al., Journal of Computational Chemistry 2004, 25(9), 1157-1174).
[0263] abbreviation
[0264] DIPEA = diisopropylethylamine, DIC = N,N'-diisopropylcarbodiimide, ESI = electrospray ionization, HOAt = 1-hydroxy-7-azabenzotriazole, TFA = trifluoroacetic acid, THF = tetrahydrofuran, DMF = dimethylformamide, DMSO = dimethyl sulfoxide, MTBE = methyl tert-butyl ether, PyAOP = ((7-azabenzotriazol-1-yloxy)tripyrrolidino- hexafluorophosphate), Fmoc = fluorenylmethoxycarbonyl, Boc = tert-butyloxycarbonyl, Cbz-Cl = benzyl chloroformate, Pfp = pentafluorophenyl, EDTA = ethylenediaminetetraacetic acid, Dab = 2,4-diaminobutyric acid, pro = proline, NMR = nuclear magnetic resonance, TEMPO = (2,2,6,6-tetramethylpiperidin-1-yl)oxy or oxidanyl, TLC = thin layer chromatography, DKP = diketopiperazine, HPLC = high performance liquid chromatography, HR = high resolution, LC = liquid chromatography, LR = low resolution, MS = mass spectrometry.
[0265] Experimental procedure and characterization data
[0266] Synthesis and characterization of building blocks
[0267] Synthesis of 2a on a multi-kilogram scale
[0268]
[0269] Synthesis of S2a
[0270] (2S,4R)-1-((Benzyloxy)carbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (S2a) - purified yield: 27.7 kg, 91%.
[0271] Five reactions were carried out in parallel. To a solution of compound 1a (3.00 kg, 22.8 mol) and NaHCO3 (4.80 kg, 57.2 mol) in H2O (18.0 L) was added CbzCl (3.71 kg, 21.7 mol) in THF (3 L), and the mixture was stirred at 20°C for 1 h. TLC (petroleum ether / ethyl acetate = 3 / 1, R f =0.00) showed that CbzCl was completely consumed, TLC (dichloromethane / methanol=5 / 1, R f=0.20) showed that the product was detected. The five reactions were combined for further processing. The reaction mixture was cooled to 0°C, and HCl (12M, 600.0mL, pH=2) was added dropwise. Then, the mixture was extracted with EtOAc (8.00L×2). The organic portion was washed with brine (5.00L) and dried over Na2SO4. The mixture was concentrated in vacuo to give compound S2a as a yellow oil. 1 H NMR (400 MHz, DMSO, rotamers observed) δ 7.29–7.38 (m, 5H), 5.04–5.12 (m, 2H), 4.21–4.30 (m, 2H), 3.36–3.47 (m, 2H), 2.12–2.20 (m, 1H), 1.88–1.98 (m, 1H).
[0272] Synthesis of S3a
[0273] (S)-1-((Benzyloxy)carbonyl)-4-oxopyrrolidine-2-carboxylic acid (S3a) - Purified yield: 15.0 kg, 92%.
[0274] Five reactions were carried out in parallel. TEMPO (148.0 g, 942 mmol) and trichloroisocyanuric acid (3.07 kg, 13.1 mol) were added to a solution of compound S2a (5.00 kg, 18.8 mol) in EtOAc (25.0 L) at 0°C. The mixture was stirred at 0°C for 3 h. TLC (dichloromethane / methanol = 10 / 1, R f =0.4) showed that the starting material was completely consumed. Five reactions were combined for further processing. The reaction mixture was filtered to remove insoluble matter. The mixture was quenched by adding Na2S2O3 (20.0 L) at 0-10°C. The combined organic layers were washed with brine (10.0 L×2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was ground with petroleum ether / MTBE=1 / 1 (10.0 L) at 25°C for 1 h, filtered and the solvent was evaporated to provide compound S3a as a white solid. From WuXi Apptec 1 H NMR (400 MHz, CDCl3, rotamers observed) δ 9.05–9.09 (m, 1H), 7.26–7.37 (m, 5H), 5.16–5.27 (m, 2H), 4.86–4.92 (m, 1H), 3.89–4.02 (m, 2H), 2.94–3.06 (m, 1H), 2.67–2.77 (m, 1H).
[0275] Synthesis of 2a
[0276] 1-Benzyl-2-(tert-butyl)(S)-4-oxopyrrolidine-1,2-dicarboxylate (2a) - Purification yield: 10.0 kg, 69%
[0277] Four reactions were carried out in parallel. To a solution of compound S3a (3.00 kg, 11.4 mol) in THF (12.0 L) and cyclohexane (12.0 L) was added tert-butyl 2,2,2-trichloroacetimidate (4.98 kg, 22.7 mol) at 12°C. Diethyloxonio (trifluoro) boranuide (161.0 g, 1.14 mol) was added dropwise to the mixture at 0°C. The mixture was stirred at 12°C for 2 h. TLC (dichloromethane / methanol = 10 / 1, R f =0.8) showed that the starting material was completely consumed. The four reactions were combined for further processing. The mixture was quenched by NaHCO3 (4.00 L), adjusted to pH = 8, then washed with brine (5.00 L), and dried over Na2SO4. The organic layer was concentrated to give a residue. The residue was filtered to remove insoluble material, and the solution was concentrated in vacuo to give compound 2a as a brown oil. 1 H NMR (400 MHz, CDCl3, rotamers observed) δ7.32–7.38 (m, 5H), 5.12–5.26 (m, 2H), 4.68–4.76 (m, 1H), 3.88–4.02 (m, 2H), 2.90–3.00 (m, 1H), 2.52–2.58 (m, 1H), 1.41 (s, 9H, rotamers). HRMS (ESI-TOF) m / z: [M+Na] + C 17 H 21 NO5Na calculated: 342.1312; found: 342.1311.
[0278] Synthesis of 2b on a multi-kilogram scale
[0279]
[0280] Synthesis of S2b
[0281] (2R,4R)-1-((Benzyloxy)carbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (S2b) - purified yield: 15.0 kg, 82%.
[0282] Three reactions were carried out in parallel. To a solution of compound 1b (3.00 kg, 22.8 mol) and NaHCO3 (4.80 kg, 57.2 mol) in H2O (18.0 L) was added CbzCl (3.71 kg, 21.7 mol) in THF (3.00 L), and the mixture was stirred at 20°C for 3 h. TLC (petroleum ether / ethyl acetate = 3 / 1, R f =0.00) showed that CbzCl was completely consumed, TLC (dichloromethane / methanol=5 / 1, R f =0.30) showed that the product was detected. The three reactions were combined for subsequent processing. The reaction mixture was cooled to 0°C, and HCl (12M, 600mL) was added dropwise until pH = 2. Then, the mixture was extracted with EtOAc (8.00L×2). The organic portion was washed with brine (5.00L) and dried over Na2SO4. The mixture was concentrated in vacuo to give compound S2b as a white solid. 1 H NMR (400 MHz, DMSO-d6, rotamers observed) δ 7.30–7.37 (m, 5H), 5.02–5.08 (m, 2H), 4.19–4.28 (m, 2H), 3.55–3.59 (m, 1H), 3.19–3.23 (m, 1H), 2.32–2.40 (m, 1H), 1.89–1.93 (m, 1H).
[0283] Synthesis of S3b
[0284] (R)-1-((Benzyloxy)carbonyl)-4-oxopyrrolidine-2-carboxylic acid (S3b) - Purified yield: 12.0 kg, 94%
[0285] Three reactions were carried out in parallel. TEMPO (127.5 g, 810.5 mmol) and trichloroisocyanuric acid (2.64 kg, 11.4 mol) were added to a solution of compound S2b (4.30 kg, 16.21 mol) in DCM (28.0 L) at 0°C. The mixture was stirred at 0°C for 3 h. TLC (dichloromethane / methanol=10 / 1, R f=0.40) showed that the starting material was completely consumed. The three reactions were combined for subsequent processing. The reaction mixture was filtered to remove insoluble matter. The mixture was quenched by adding Na2S2O3 (20.0 L) at 0-10°C. The combined organic layers were washed with brine (10.0 L×2), and dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was ground with petroleum ether / MTBE=1 / 1 (10.0 L) at 25°C for 1 h, filtered and the solvent was evaporated to provide compound S3b as a white solid. From WuXi Apptec 1 H NMR (400 MHz, CDCl3, rotamers observed) δ 9.15 (br, 1H), 7.32–7.35 (m, 5H), 5.15–5.28 (m, 2H), 4.84–4.90 (m, 1H), 3.88–4.00 (m, 2H), 2.92–2.99 (m, 1H), 2.70–2.74 (m, 1H).
[0286] Synthesis of 2b
[0287] 1-Benzyl-2-(tert-butyl)(R)-4-oxopyrrolidine-1,2-dicarboxylate (2b) - Purification yield: 13.0 kg, 89%
[0288] Four reactions were carried out in parallel. At 12°C, tert-butyl 2,2,2-trichloroacetimidate (4.98 kg, 22.7 mol) was added to a solution of compound S3b (3.00 kg, 11.4 mol) in THF (12.0 L) and cyclohexane (12.0 L). Diethyloxonium (trifluoro)ammonium borate (161.0 g, 1.14 mol) was added dropwise to the mixture at 0°C. The mixture was stirred at 12°C for 2 h. TLC (dichloromethane / methanol = 10 / 1, R f =1.00) showed that the starting material was completely consumed. TLC (petroleum ether / ethyl acetate=3 / 1, Rf=0.5) showed that the product was detected. The four reactions were combined for further processing. The mixture was quenched by NaHCO3 (4.00 L), adjusted to pH=8, then washed with brine (5.00 L), and dried over Na2SO4. The organic layer was concentrated to give a residue. The residue was filtered to remove insolubles and concentrated in vacuo to give compound 2b as a brown oil. From WuXi Apptec 1H NMR (400 MHz, CDCl3, rotamers observed) δ7.32–7.36 (m, 5H), 5.13–5.24 (m, 2H), 4.69–4.75 (m, 1H), 3.90–4.02 (m, 2H), 2.90–2.98 (m, 1H), 2.52–2.57 (m, 1H), 1.40 (s, 9H, rotamers). HRMS (ESI-TOF) m / z: [M+Na] + C 17 H 21 Calculated for NO5Na: 342.1312; found: 342.1312.
[0289] Synthesis of compounds 4a-d
[0290] (3S,5S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-3-amino-5-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (4a) - purified yield, 12.2 g, 71%
[0291] Compound 3a-d (38mmol) was dissolved in Na2CO3 (300mL, 0.2mol / L). Pd / C (10%wt) was added to the solution, and a balloon filled with H2 was connected through a 3-way valve. Air was removed by evacuating and backfilling H2 several times. After stirring overnight at room temperature, the reaction was completed (monitored by LCMS). CuCl2 (20mmol) was added to the stirred solution and reacted for 30 minutes. Fmoc-Cl (40mmol) dissolved in EtOAc (100mL) was added dropwise to the reaction mixture and stirred vigorously for another 2 hours. Pd / C was removed by vacuum filtration using diatomaceous earth, and the organic layer was collected, washed with saturated NaCl solution (250mL×2) and transferred to a beaker. The solution was then mixed with EDTA sodium salt solution (250mL, 0.2M) and stirred vigorously overnight. The product 4a-d was isolated under vacuum filtration as a white solid. This four-step reaction sequence was carried out without any chromatography. 1H NMR (500 MHz, DMSO) δ 8.78 (s, 2H), 7.91 (t, J = 7.4 Hz, 2H), 7.64 (d, J = 7.5 Hz, 2H, rotamer), 7.43 (t, J = 7.3 Hz, 2H), 7.34–7.31 (m, 2H), 4.42–4.15 (m, 4H, rotamer), 4.04 (d, J = 11.5 Hz, 1H, rotamer), 3.58 (d, J = 11.5 Hz, 1H, rotamer), 2.88 (dd, J = 13.4, 8.5 Hz, 1H, rotamer), 2.21 (dd, J = 13.4, 8.8 Hz, 1H, rotamer), 1.40 (s, 9H). 13 C NMR (125 MHz DMSO, rotamers observed) δ 172.1, 171.7, 170.8, 170.7, 154.1, 154.0, 144.2, 144.1, 144.0, 143.7, 141.2, 128.3, 128.2, 127.6, 125.9, 125.7, 125.6, 120.6, 81.9, 81.5, 67.7, 67.3, 62.0, 61.0, 60.2, 59.9, 55.1, 54.3, 47.1, 46.9, 38.9, 37.9, 28.1, 28.00; HRMS (ESI-TOF) m / z: [M+H] + C 25 H 29 Calculated for N2O6: 453.2020; found: 453.2016.
[0292] (3R,5S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-3-amino-5-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (4b) - purified yield, 13.0 g, 74%.
[0293] 1 H NMR (500 MHz, DMSO) δ8.74 (s, 2H), 7.91 (d, J = 7.5 Hz, 2H), 7.72–7.66 (m, 2H), 7.44 (t, J = 7.4 Hz, 2H), 7.36–7.31 (m, 2H), 4.61, 4.41 (m, 1H, rotamer), 4.40–4.04 (m, 2H, rotamer), 3.99 (m, 1H, rotamer), 3.85, 3.76 (d, J = 12.2 Hz, 1H, rotamer), 2.77, 2.67 (dd, J = 14.1, 9.0 Hz, 1H, rotamer), 2.50 (dd, J = 14.3, 7.8 Hz, 1H, rotamer), 1.40 (d, J = 5.3 Hz, 9H);13 C NMR (125 MHz, DMSO, rotamers observed) δ 170.9, 170.3, 169.9, 163.6, 154.0, 153.8, 144.1, 144.0, 143.7, 141.2, 141.1, 128.3, 128.2, 127.7, 127.6, 125.9, 125.8, 125.7, 120.7, 120.6, 82.2, 81.8, 68.0, 67.7, 63.9, 63.0, 58.9, 58.4, 55.0, 54.4, 47.0, 46.9, 38.1, 28.0; HRMS (ESI-TOF) m / z: [M+H] + C 25 H 29 Calculated for N2O6: 453.2020, found: 453.2028.
[0294] (3R,5R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-3-amino-5-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (4c) - purified yield, 10.9 g, 64%.
[0295] 1 H NMR (500 MHz, DMSO) δ 8.78 (s, 2H), 7.91 (t, J = 7.4 Hz, 2H), 7.64 (d, J = 7.5 Hz, 2H, rotamer), 7.43 (t, J = 7.3 Hz, 2H), 7.34–7.31 (m, 2H), 4.42–4.15 (m, 4H, rotamer), 4.04 (d, J = 11.4 Hz, 1H, rotamer), 3.58 (d, J = 11.5 Hz, 1H, rotamer), 2.88, 2.84 (dd, J = 13.3, 8.5 Hz, 1H, rotamer), 2.24, 2.21 (dd, J = 13.3, 8.8 Hz, 1H, rotamer), 1.41 (s, 9H); 13 C NMR (125 MHz, DMSO, rotamers observed) δ 172.1, 171.7, 170.9, 170.8, 154.1, 154.0, 144.2, 144.1, 144.0, 143.7, 141.1, 128.3, 128.2, 127.6, 125.9, 125.7, 125.6, 121.9, 120.6, 120.5, 81.9, 81.5, 67.7, 67.3, 62.0, 61.0, 60.2, 59.9, 55.1, 54.3, 47.1, 46.9, 38.9, 37.9, 28.1, 28.0; HRMS (ESI-TOF) m / z: [M+H]+ C 25 H 29 Calculated for N2O6: 453.2020, found: 453.2017.
[0296] (3R,5S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-3-amino-5-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (4d) - purified yield, 14.7 g, 85%.
[0297] 1 H NMR (500 MHz, DMSO) δ8.75 (s, 2H), 7.91 (d, J = 7.6 Hz, 2H), 7.72–7.66 (m, 2H), 7.44 (t, J = 7.5 Hz, 2H), 7.36–7.31 (m, 2H), 4.61, 4.41 (m, 1H, rotamer), 4.40–4.04 (m, 2H, rotamer), 3.99 (m, 1H, rotamer), 3.85, 3.78 (d, J = 12.2 Hz, 1H, rotamer), 2.77, 2.67 (dd, J = 14.1, 7.7 Hz, 1H, rotamer), 2.53, 2.45 (dd, J = 14.3, 7.6 Hz, 1H, rotamer), 1.40 (d, J = 5.3 Hz, 9H); 13 C NMR (125 MHz, DMSO, rotamers observed) δ 170.8, 170.3, 169.9, 163.6, 154.0, 153.8, 144.1, 143.7, 141.2, 141.1, 128.4, 128.2, 127.7, 127.6, 125.9, 125.8, 125.7, 120.7, 82.2, 81.8, 68.0, 67.7, 63.8, 62.9, 58.8, 58.4, 54.9, 54.6, 47.0, 38.1, 28.0; HRMS (ESI-TOF) m / z: [M+H] + C 25 H 29 Calculated for N2O6: 453.2020, found: 453.2029.
[0298] Synthesis of compounds 5a-d
[0299]
[0300] Synthesis of functionalized bisamino acid 5a
[0301] (3S,5S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-5-(tert-butoxycarbonyl)-3-((naphthalen-2-ylmethyl)amino)pyrrolidine-3-carboxylic acid (5a) - purified yield, 1.82 g, 61%.
[0302] 2-Naphthaldehyde (7.5mmol) is added into a 100mL round-bottomed flask containing compound 4a (5mmol) dissolved in 25mL MeOH. The solution is stirred for 30min, while NaBH3CN (7.5mmol) is added and stirred overnight. The reaction process is determined by LCMS, and, if incomplete, additional aldehyde and reducing agent are added. When reductive alkylation is complete, the solution is transferred to a round-bottomed flask containing 10g diatomaceous earth. The solvent is removed under reduced pressure, and the dried powder is then transferred to a loaded column for flash chromatography. The mobile phase of 20% MeOH for normal phase separation DCM / in DCM is carried out using a 0-100% gradient. The fractions containing the pure product are collected and the solvent is removed under reduced pressure to obtain functionalized diamino acid 5a. Purity is checked by LCMS. 1 H NMR (500MHz, DMSO) δ7.90–7.83 (m, 6H), 7.68–7.63 (m, 2H), 7.53–7.38 (m, 5H), 7.34–7.28 (m, 2H), 4.39, 4.32 (m, 1H, rotamer), 4.23 (m, 2H, rotamer), 4.15 (m, 1H, rotamer), 4.00, 3.90 (m, 1H, rotamer), 3.88 (m, 1H), 3.82 (m, 1H), 3.52, 3.46 (d, J = 10.8 Hz, 1H, rotamer), 2.76–2.68 (m, 1H, rotamer), 2.15, 2.07 (dd, J = 12.8, 6.0 Hz, 1H, rotamer), 1.36 (s, 9H); 13 C NMR (125MHz, DMSO) δ174.4,171.2,170.8,154.3,144.3,144.1,143.9,14 1.1,137.2,133.3,132.7,128.2,128.0,127.6,127.4,127.0,126.5,126. 1,125.8,125.7,125.6,120.6,81.3,81.0,68.2,67.5,67.3,59.7,59.3, 54.9,54.4,49.0,47.2,46.9,39.1,38.0,28.1; HRMS(ESI-TOF)m / z:[M+H] + C 36 H 37Calculated for N2O6: 593.2624, found: 593.2638.
[0303] Synthesis of functionalized bisamino acid 5b
[0304] (3R,5S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-5-(tert-butoxycarbonyl)-3-(isopentylamino)pyrrolidine-3-carboxylic acid (5b) - purified yield, 2.34 g, 90%.
[0305] Isovaleraldehyde (7.5mmol) is added into a 100mL round-bottomed flask containing compound 4b (5mmol) suspended in 25mL MeOH / DCM. The solution is stirred for 30min, while NaBH3CN (7.5mmol) is added and stirred overnight. The reaction process is determined by LCMS, and, if incomplete, additional aldehyde and reducing agent are added. When reductive alkylation is complete, the solution is transferred to a round-bottomed flask containing 10g diatomaceous earth. The solvent is removed under reduced pressure, and the dried powder is then transferred to a loaded column for flash chromatography. The mobile phase of 20% MeOH for normal phase separation DCM / in DCM is carried out using a 0-100% gradient. The fractions containing the pure product are collected and the solvent is removed under reduced pressure to obtain functionalized diamino acid 5b. Purity is checked by LCMS. 1 H NMR (500 MHz, DMSO) δ7.91–7.89 (m, 2H), 7.68–7.64 (m, 2H), 7.44–7.41 (m, 2H), 7.35–7.30 (m, 2H), 4.55, 4.49 (dd, J=9.1, 5.6 Hz, 1H, rotational isomerism), 4.47–4.45 (m, 1H), 4.27, 4.23 (m, 1H, rotational isomerism), 4.15 (m, 1H, rotational isomerism). structure), 4.05 (t, J = 13.6 Hz, 1H), 3.84 (d, J = 12.7 Hz, 1H, rotational isomerism), 3.07–2.83 (m, 3H), 2.63, 2.55 (dd, J = 14.8, 5.4 Hz, 1H, rotational isomerism), 1.67–1.61 (m, 1H), 1.53–1.49 (m, 2H), 1.40 (s, 9H, rotational isomerism), 0.89 (d, J = 6.6 Hz, 6H); 13CNMR (125MHz, DMSO) δ170.2,169.9,169.4,169.3,153.8,153.7,144.1,143.7,141.2,128.3,127.6,125.7,125.5,120.6,119.2,116.9,11 4.6,112.3,82.3,81.9,69.0,68.1,67.9,58.9,58.5,53.5,52.9,47.0,46.9,43.0,36.6,35.3,27.9,25.7,22.3; HRMS(ESI-TOF)m / z:[M+H] + C 30 H 39 Calculated for N2O6: 523.2803, found: 523.2797.
[0306] Synthesis of functionalized bisamino acid 5c
[0307] (3R,5R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-5-(tert-butoxycarbonyl)-3-((pyridin-4-ylmethyl)amino)pyrrolidine-3-carboxylic acid (5c) - purified yield, 2.16 g, 79%.
[0308] 4-Pyridinecarboxaldehyde (7.5mmol) is added into a 100mL round-bottomed flask containing compound 4c (5mmol) dissolved in 25mL MeOH. The solution is stirred for 30min, while NaBH3CN (7.5mmol) is added and allowed to stand overnight. The reaction process is determined by LCMS, and, if incomplete, additional aldehydes and reducing agents are added. When reductive alkylation is complete, the solution is transferred to a round-bottomed flask containing 10g diatomaceous earth. The solvent is removed under reduced pressure, and the dried powder is then transferred to a loaded column for flash chromatography. The mobile phase of 20% MeOH for normal phase separation DCM / in DCM is carried out using a 0-100% gradient. The fractions containing the pure product are collected and the solvent is removed under reduced pressure to obtain functionalized diamino acid 5c. Purity is checked by LCMS. 1H NMR (500 MHz, DMSO) δ 8.46–8.43 (m, 2H), 7.89 (d, J = 7.6 Hz, 2H), 7.69–7.64 (m, 2H), 7.43–7.39 (m, 2H), 7.36–7.30 (m, 4H), 4.37–4.04 (m, 4H), 3.96, 3.85 (d, J = 10.2 Hz, 1H, rotational isomerism), 3.63 (q, J = 13.9 Hz, 2H), 3.32, 3.24 (d, J = 10.2 Hz, 1H, rotational isomerism), 2.64–2.55 (m, 1H, rotational isomerism), 1.93, 1.86 (dd, J = 12.3, 5.9 Hz, 1H, rotational isomerism), 1.35 (s, 9H, rotational isomerism); 13 C NMR (125MHz, DMSO) δ176.3,171.7,171.3,154.4,154.3,151.1,149.6,144.5,144.2,143.9,141.1,128.2,127.6,125.8,125.7,125. 6,123.4,120.6,80.8,80.5,69.0,68.0,67.3,67.1,60.0,59.7,55.8,55.2,48.1,47.2,47.0,39.1,28.1; HRMS(ESI-TOF)m / z:[M+H] + C 31 H 34 Calculated for N3O6: 544.2442, found: 544.2445.
[0309] Synthesis of functionalized bisamino acid 5d
[0310] (3S,5R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-5-(tert-butoxycarbonyl)-3-((3,4-dichlorobenzyl)amino)pyrrolidine-3-carboxylic acid (5d) - purified yield, 2.67 g, 87%.
[0311] 3,4-dichlorobenzaldehyde (7.5mmol) is added to a 100mL round-bottomed flask containing compound 4d (5mmol) suspended in 25mL MeOH. The solution is stirred for 30min, while NaBH3CN (7.5mmol) is added and allowed to stand overnight. The reaction process is determined by LCMS, and, if incomplete, additional aldehydes and reducing agents are added. When the reductive alkylation is complete, the solution is transferred to a round-bottomed flask containing 10g diatomaceous earth. The solvent is removed under reduced pressure, and the dried powder is then transferred to a loaded column for flash chromatography. The mobile phase of 20% MeOH for normal phase separation DCM / in DCM is carried out using a 0-100% gradient. The fractions containing the pure product are collected and the solvent is removed under reduced pressure to obtain functionalized diamino acid 5d. Purity is checked by LCMS. 1 H NMR (500 MHz, DMSO) δ 7.91–7.86 (m, 2H), 7.68 (d, J = 7.5 Hz, 1H, rotational isomerism), 7.59–7.49 (m, 3H), 7.43–7.22 (m, 5H), 4.36–4.27 (m, 1H, rotational isomerism), 4.22–4.11, 4.04 (m, 3H, rotational isomerism), 3.73–3.45 (m, 4H), 2.34, 2.10 (m, 1H, rotational isomerism), 2.21 (dd, J = 12.8, 8.5 Hz, 1H, rotational isomerism), 1.38 (s, 9H, rotational isomerism); 13 C NMR (125MHz, DMSO) δ174.8,174.7,172.1,171.6,154.5,154.4,144.3,144.1,143.7,14 1.1,131.2,131.1,130.6,130.5,130.1,130.0,129.4,129.3,128.5,128.3,128.1,127 .6,127.5,125.8,125.6,125.5,125.4,120.7,120.6,81.3,80.9,69.4,68.6,67.5,67. 0,59.9,59.4,55.2,54.2,47.2,47.1,46.9,38.9,28.1,28.0; HRMS(ESI-TOF)m / z:[M+H] + C 32 H 33 Calculated for Cl2N2O6: 611.1710, found: 611.1714.
[0312] Synthesis of compounds 6a-d
[0313]
[0314] Synthesis of functionalized pentafluorophenyl ester 6a
[0315] 1-((9H-Fluoren-9-yl)methyl)2-(tert-butyl)4-(perfluorophenyl)(2S,4S)-4-((naphthalen-2-ylmethyl)amino)pyrrolidine-1,2,4-tricarboxylate (6a) - purified yield, 1.07 g, 71%.
[0316] Compound 5a (2mmol) and pentafluorophenol (10mmol) are weighed and dissolved in 10mL DCM. DIC (4mmol) is added, and the reaction is stirred overnight. The completion of the reaction is checked by LCMS, and then the reaction is transferred to a 50mL round-bottomed flask comprising diatomite (5g). At room temperature, white powder is obtained by removing the solvent under reduced pressure. Use dry diatomite to fill the column, thus use hexane / EtOAc, use 5-100% EtOAc gradient to run flash chromatography. The fraction comprising the pure product is collected under reduced pressure to obtain 6a as a light yellow solid. 1 H NMR (500 MHz, CDCl3, rotamers observed) δ7.83–7.74 (m, 6H), 7.64–7.57 (m, 2H), 7.51–7.46 (m, 3H), 7.42–7.36 (m, 2H), 7.32–7.25 (m, 2H), 4.56–4.46 (m, 2H), 4.38–4.21 (m, 3H), 4.00–3.84 (m, 3H), 2.94 (m, 1H), 2.50 (dt, J = 12.9, 4.7 Hz, 1H, rotamers), 1.43 (s, 9H, rotamers); 13 C NMR (125 MHz, CDCl3, rotamers observed) δ 170.2, 170.1, 169.7, 169.6, 154.4, 144.2, 144.0, 143.7, 143.5, 141.3, 141.2, 136.0, 135.9, 133.4, 132.9, 128.3, 127.8, 127.7, 127.1, 127.0, 126.9, 126.6, 126.5,126.2,125.9,125.3,125.2,125.1,125.0,120.0,82.2,82.1,68.8,68.0,67.9,58.9,58 .7,54.6,54.2,49.7,49.0,47.3,47.1,39.5,38.3,28.1,28.0,24.6; HRMS(ESI-TOF)m / z:[M+H] + C 42 H 36Calculated for F5N2O6: 759.2423, found: 759.2488.
[0317] Synthesis of functionalized pentafluorophenyl ester 6b
[0318] 1-((9H-fluoren-9-yl)methyl)2-(tert-butyl)4-(perfluorophenyl)(2S,4R)-4-(isopentylamino)pyrrolidine-1,2,4-tricarboxylate (6b) - purified yield, 1.01 g, 73%.
[0319] Compound 5b (2mmol) and pentafluorophenol (10mmol) are weighed and dissolved in 10mL DCM. DIC (4mmol) is added and the reaction is stirred overnight. The completion of the reaction is checked by LCMS, and then the reaction is transferred to a 50mL round-bottomed flask comprising diatomite (5g). At room temperature, a white powder is obtained by removing the solvent under reduced pressure. Column is filled with dry diatomite, thus using hexane / EtOAc, using 5-100% EtOAc gradient to run flash chromatography. The fractions comprising the pure product are collected under reduced pressure to obtain 6b (50.7%) as a white solid. 1 H NMR (500 MHz, CDCl3, rotamers observed) δ7.78–7.76 (m, 2H), 7.69–7.59 (m, 2H), 7.43–7.39 (m, 2H), 7.34–7.30 (m, 2H), 4.55–4.20 (m, 4H), 4.05 (t, J = 13.6 Hz, 1H), 4.02, 3.84 (m, 1H, rotamers), 2.63–2.43 (m, 4H), 1.46 (s, 9H, rotamers); 1.41 (q, J = 7.2 Hz, 2H), 1.22 (d, J = 6.4 Hz, 1H), 0.92–0.89 (m, 6H); 13 C NMR (125 MHz, CDCl3, rotamers observed) δ 171.0, 170.7, 168.8, 168.7, 154.7, 144.2, 144.0, 143.8, 143.5, 141.4, 141.3, 127.8, 127.7, 127.2, 127.1, 125.5, 125.2, 125.1, 120. 0,82.2,82.0,68.2,68.1,67.7,67.4,59.2,58.9,54.6,54.1,47.2,47.1,42.7,42 .7,39.4,39.4,38.9,37.8,28.0,26.0,25.9,22.6,22.5; HRMS(ESI-TOF)m / z:[M+H] + C 36 H38 Calculated for F5N2O6: 689.2645, found: 689.2649.
[0320] Synthesis of functionalized pentafluorophenyl ester 6c
[0321] 1-((9H-fluoren-9-yl)methyl)2-(tert-butyl)4-(perfluorophenyl)(2R,4R)-4-((pyridin-4-ylmethyl)amino)pyrrolidine-1,2,4-tricarboxylate (6c) - purified yield, 0.752 g, 53%.
[0322] Compound 5c (2mmol) and pentafluorophenol (10mmol) are weighed and dissolved in 10mL DCM. DIC (4mmol) is added, and the reaction is stirred overnight. The completion of the reaction is checked by LCMS, and then the reaction is transferred to a 50mL round-bottomed flask comprising diatomite (5g). At room temperature, white powder is obtained by removing the solvent under reduced pressure. With dry diatomite loading, flash chromatography is run using hexane / EtOAc, using 5-100% EtOAc gradient. The fractions comprising the pure product are collected under reduced pressure to obtain 6c as a white solid. 1 H NMR (500 MHz, CDCl3, rotamers observed) δ 8.58–8.45 (m, 2H), 7.78–7.75 (m, 2H), 7.64–7.56 (m, 2H), 7.42–7.37 (m, 4H), 7.32–7.25 (m, 2H), 4.55–4.47 (m, 2H), 4.41–4.33 (m, 1H), 4.29–4.10 (m, 2H), 3.89–3.74 (m, 3H), 2.96–2.86 (m, 1H, rotamers), 2.47 (td, J = 13.8, 3.9 Hz, 1H), 1.44 (d, 9H, rotamers); 13 C NMR (125 MHz, CDCl3, rotamers observed) δ 175.6, 175.5, 171.1, 171.0, 170.2, 169.2, 169.1, 154.4, 149.5, 149.4, 148.5, 148.4, 147.6, 144.1, 143.9, 143.6, 143.4, 141.3, 127.8, 12 7.2,127.1,127.0,125.2,125.1,125.0,123.6,123.5,120.0,82.5,82.4,68.7,67.7, 58.8,58.6,54.4,54.0,48.1,47.3,47.1,39.5,38.2,28.1; HRMS(ESI-TOF)m / z:[M+H]+ C 37 H 33 Calculated for F5N3O6: 710.2284, found: 710.2289.
[0323] Synthesis of functionalized pentafluorophenyl ester 6d
[0324] 1-((9H-fluoren-9-yl)methyl)2-(tert-butyl)4-(perfluorophenyl)(2R,4S)-4-((3,4-dichlorobenzyl)amino)pyrrolidine-1,2,4-tricarboxylate (6d) - purified yield, 1.10 g, 71%.
[0325] Compound 5d (2mmol) and pentafluorophenol (10mmol) are weighed and dissolved in 10mL DCM. DIC (4mmol) is added, and the reaction is stirred overnight. The completion of the reaction is checked by LCMS, and then the reaction is transferred to a 50mL round-bottomed flask comprising diatomite (5g). At room temperature, white powder is obtained by removing the solvent under reduced pressure. Use dry diatomite to fill the column, thus use hexane / EtOAc, use 5-100% EtOAc gradient to run flash chromatography. The fractions comprising the pure product are collected under reduced pressure to obtain 6d as a white solid. 1 H NMR (500 MHz, CDCl3, rotamers observed) δ7.78–7.51 (m, 4H), 7.45–7.14 (m, 7H), 4.58–4.45 (m, 2H, rotamers), 4.39–4.30 (m, 1H, rotamers), 4.22 (t, J = 7.1 Hz, 1H), 4.10–4.02 (m, 1H), 3.97–3.64 (m, 3H), 2.63–2.46 (m, 2H), 1.46 (s, 9H, rotamers); 13 C NMR (125 MHz, CDCl3, rotamers observed) δ 170.7, 170.5, 168.4, 168.3, 154.8, 154.6, 144.1, 143.9, 143.7, 143.4, 141.3, 141.3, 139.2, 139.1, 132.7, 131.6, 130.5, 129.9, 129.8, 127.8, 12 7.2,127.1,125.4,125.1,125.0,124.9,120.1,120.0,119.9,82.5,82.3,68.2,67.5,59 .1,58.9,54.3,53.6,47.7,47.6,47.2,47.1,39.3,38.2,28.0; HRMS(ESI-TOF)m / z:[M+H] + C38 H 32 Calculated for Cl2F5N2O6: 777.1481, found: 777.1556.
[0326] Solid Phase Synthesis of Spiro Oligomers
[0327] General process of solid phase synthesis
[0328] General process of resin loading
[0329] The solid phase synthesis of spirocyclic oligomer is carried out on a microwave peptide synthesizer.Cl-TCP (Cl) Protide resin (100mg, 0.05mmol, 0.5mmol / g load) is weighed into a 25mL reaction vessel.Fmoc-Pro-OH is weighed into a 2mL centrifuge tube and dissolved in anhydrous DMF (2mL) with DIPEA (168 μL, 1mmol).Then the solution is added to the resin in the reaction vessel once, and it is reacted 30min at 50°C under Ar bubbling.After the solution is drained, the resin is washed three times with 2mL DMF.Unreacted trityl chloride is end-capped at room temperature for 10min with 2mL end-capping solution comprising the methanol / DIPEA / DCM of 1:3:17, and the resin is washed three times with DMF.
[0330] General process of Fmoc deprotection
[0331] All deprotections were accomplished with 20% piperidine in DMF (2 mL) (1 x 4 min, 60 °C). After each Fmoc deprotection, the resin was washed with DMF (3 x 1 mL).
[0332] General process of coupling of building blocks
[0333] A solution of the building block (0.1 mmol, 2 equivalents) in 1 mL of anhydrous DMF was added to the resin in the reaction vessel. Then, a solution of HOAt (27.2 mg, 0.2 mmol) and DIPEA (69.7 μL, 0.4 mmol) in 1 mL of anhydrous DMF was added. The reaction mixture was heated at 50° C. for 1 hour. Completion of the reaction was confirmed by testing cleavage with LCMS after washing with DMF.
[0334] General process of coupling of Fmoc-Dab(Boc)-OH
[0335] Fmoc-Dab(Boc)-OH (63.9 mg, 0.15 mmol, 3 eq.) in 1 mL of DMF was transferred into the reactor together with a mixture of PyAOP (78.2 mg, 0.15 mmol), DIPEA (52.3 mL, 0.3 mmol) and DMF (2 mL), and they were left to react for 5 min at 50° C. The completion of the reaction was confirmed by testing cleavage with LCMS after washing with DMF.
[0336] General process of lysis and DKP closure
[0337] Final cleavage was achieved by using TFA (2 mL x 2) for 30 min at room temperature. The product was collected in a 50 mL centrifuge tube and transferred to a 20 mL glass vial. It was placed in a heating block and stirred at 40°C overnight.
[0338] Solid phase synthesis of T1
[0339] The first residue Fmoc-Pro-OH (169mg, 0.5mmol) is loaded onto resin (100mg, 0.05mmol, 0.5mmol / g loading) with the general process of resin loading and deprotected with the general process of Fmoc deprotection. The general process of coupling of building block and Fmoc deprotection adopts 6a (75.8mg, 0.1mmol, 2 equivalents), then 6b (68.8mg, 0.1mmol), 6c (71mg, 0.1mmol) and 6d (77.3mg, 0.1mmol) to carry out. Then, Fmoc-Dab (Boc) -OH (63.9mg, 0.15mmol) is coupled and deprotected as mentioned above. Finally, the cracking of T1 and DKP closure are carried out according to the general process. After confirmation of completion of DKP closure by LCMS, the product was precipitated in cold ether and purified by preparative HPLC (25%-95% gradient of MeCN in water with 0.1% TFA). Purified fractions containing the product were collected and then lyophilized to give the spirocyclic oligomer T1 as a white powder. T1-purification yield, 18 mg, 30%; HPLC purity, 98%; retention time, 3.122 min. HRMS (ESI-TOF) m / z: [M+H] + C 62 H 67 Cl2N 12 O 10 Calculated: 1209.44, Found: 1209.44.
[0340] Solid phase synthesis of T2
[0341] The first residue Fmoc-Pro-OH (169mg, 0.5mmol) is loaded onto resin (100mg, 0.05mmol, 0.5mmol / g loading) with the general process of resin loading and deprotected with the general process of Fmoc deprotection. The general process of coupling of building block and Fmoc deprotection adopts 6d (77.3mg, 0.1mmol, 2 equivalents), then 6c (71mg, 0.1mmol), 6b (68.8mg, 0.1mmol) and 6a (75.8mg, 0.1mmol) to carry out. Then, as mentioned above, Fmoc-Dab (Boc) -OH (63.9mg, 0.15mmol) is coupled and deprotected. Finally, the cracking of T2 and DKP closure are carried out according to the general process. After confirmation of completion of DKP closure by LCMS, the product was precipitated in cold ether and purified by preparative HPLC (25%-95% gradient of MeCN in water with 0.1% TFA). Purified fractions containing the product were collected and then lyophilized to give the spirocyclic oligomer T2 as a white powder. T2-purification yield, 16 mg, 27%; HPLC purity, 96%; retention time, 3.297 min. HRMS (ESI-TOF) m / z: [M+H] + C 62 H 66 Cl2N 12 O 10 Calculated: 1209.44, found: 1209.45.
[0342] Solid phase synthesis of T3
[0343] The first residue Fmoc-Pro-OH (169mg, 0.5mmol) is loaded onto resin (100mg, 0.05mmol, 0.5mmol / g loading) with the general process of resin loading and deprotected with the general process of Fmoc deprotection. The general process of coupling of building block and Fmoc deprotection adopts 6b (68.8mg, 0.1mmol, 2 equivalents), then 6d (77.3mg, 0.1mmol), 6a (75.8mg, 0.1mmol) and 6c (71mg, 0.1mmol) to carry out. Then, as mentioned above, Fmoc-Dab (Boc) -OH (63.9mg, 0.15mmol) is coupled and deprotected. Finally, the cracking of T3 and DKP closure are carried out according to the general process. After confirmation of completion of DKP closure by LCMS, the product was precipitated in cold ether and purified by preparative HPLC (25%-95% gradient of MeCN in water with 0.1% TFA). Purified fractions containing the product were collected and then lyophilized to give the spirocyclic oligomer T3 as a white powder. T3-purification yield, 15 mg, 24%; HPLC purity, >99%; retention time, 3.515 min. HRMS (ESI-TOF) m / z: [M+H] + C 62 H 67 Cl2N 12 O 10 Calculated: 1209.44, found: 1209.45.
[0344] Solid phase synthesis of T4
[0345] The first residue Fmoc-Pro-OH (169mg, 0.5mmol) is loaded onto resin (100mg, 0.05mmol, 0.5mmol / g loading) with the general process of resin loading and deprotected with the general process of Fmoc deprotection. The general process of coupling of building block and Fmoc deprotection adopts 6c (71mg, 0.1mmol, 2 equivalents), then 6d (77.3mg, 0.1mmol), 6a (75.8mg, 0.1mmol) and 6b (68.8mg, 0.1mmol) to carry out. Then, as mentioned above, Fmoc-Dab (Boc) -OH (63.9mg, 0.15mmol) is coupled and deprotected. Finally, the cracking of T4 and DKP closure are carried out according to the general process. After confirmation of completion of DKP closure by LCMS, the product was precipitated in cold ether and purified by preparative HPLC (25%-95% gradient of MeCN in water with 0.1% TFA). Purified fractions containing the product were collected and then lyophilized to give the spirocyclic oligomer T4 as a white powder. T4-purification yield, 19 mg, 32%; HPLC purity, >99%; retention time, 3.333 min. HRMS (ESI-TOF) m / z: [M+H] + C 62 H 67 Cl2N 12 O 10 Calculated: 1209.44, found: 1209.45. (2S,4R)-1-((Benzyloxy)carbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (S2a).
[0346] The disclosure of each patent, patent application and publication cited herein is hereby incorporated by reference in its entirety. Although the present invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of the present invention may be devised by other skilled in the art without departing from the true spirit and scope of the present invention. The appended claims are intended to be interpreted as including all such embodiments and equivalent variations.
Claims
1. A method comprising reacting a compound of formula I with R 1 X, R 1 C(O)H or R 1 C(O)R 2 contacting in the presence of a reducing agent and under conditions and for a period of time effective to produce a compound of formula II: in: R 1 Selected from amino acids, β-amino acids, sugars, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 The group consisting of alkynyl, optionally substituted aryl, and any combination thereof; R 2 Absent or selected from H, amino acids, β-amino acids, sugars, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 The group consisting of alkynyl, optionally substituted aryl, and any combination thereof; or R 1 and R 2 Connect to form C 3-8 Cycloalkyl; X is a leaving group; R 4 is a protecting group; x is an integer 1 or 2; and z is an integer 1 or 2; The condition is that both x and z are not 2 at the same time; in: y is an integer of 0 or 1; provided that when the compound of formula I is combined with R 1 When X reacts, y is an integer 0 and R 2 Does not exist.
2. The method according to claim 1, wherein R 1 and R 2 Independently by C 0-6 Alkyl OH, C 0-6 Alkyl SH, C 0-6 Alkyl NH2, C 0-6 Alkyl-OC 0-6 Alkyl, C 0-6 Alkyl-SC 0-6 Alkyl, C 0-6 Alkyl C(O)OH, C 0-6 Alkyl C(O)(C 1-6 Alkyl), C 0-6 Alkyl C(O)O(C 1-6 Alkyl), C 0-6 Alkyl N3, C 0-6 Alkyl C(O)NH2, C 0-6 Alkyl-C(O)N(C 1-6 alkyl)OH, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 5-7 cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, -NHC(NH2)(=N(C 0-6 alkyl)), -NHC(NH2)(=S(C 0-6 alkyl)), nucleobase, or amino acid substitution; wherein any carbon atom of the alkyl, alkenyl or alkynyl group is optionally replaced by O, S, SO, SO2 or NR 7 Heteroatom substitution; R 7 Choose from H, C 1-4 Alkyl, C 3-4 Alkenyl, C 3-4 Alkynyl, C 1-4 A group consisting of a bridged alkyl group, and any combination thereof, wherein a bridge is formed between the nitrogen atom and the carbon atom of the chain containing the heteroatom, thereby forming a ring, The ring is optionally 1 fused; and Ar 1 Selected from optionally substituted C 3-6 The group consisting of cycloalkyl, heterocyclyl, aryl, heteroaryl, and any combination thereof.
3. The method according to claim 2, wherein Ar 1 The invention is selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, and anthracenyl; or a heterocyclic aromatic group selected from the group consisting of 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isotriazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3, 5-triazinyl, 1,3,5-trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolyl, benzo[b]furanyl, benzo[b]thienyl, 1H-indazolyl, benzimidazolyl, benzothiazolyl, purinyl, 4H-quinolizinyl, quinolyl, 1,2,3,4-tetrahydroquinolyl, isoquinolyl, 1,2,3,4-tetrahydroisoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and any combination thereof.
4. The method according to claim 2 or 3, wherein: Ar 1 Optionally H, halogen, OH, NO2, -SO3H, CF3, OCF3, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Alkoxy, OC 3-4 alkenyl, -O-benzyl, -O-phenyl, 1,2-methylenedioxy, -NR 5 R 6 、-C(O)OH、-C(O)(C 1-6 alkyl), C(O)O(C 1-6 alkyl), -C(O)NH(C 1-6 alkyl), -C(O)NH(C 3-5 alkenyl), -C(O)N(C 1-6 Alkyl)(C 1-6 alkyl), -C(O)(C 3-5 Alkenyl)(C 3-6 alkyl), morpholinyl, piperidinyl, -O-Ar 2 、-CH2-(CH2) q -Ar 2 、-O-(CH2) q -Ar 2 、-(CH2) q -O-Ar 2 , or -CH=CH-Ar 2 One or more substitutions in; Where R 5 and R 6 Independently selected from H, C 1-6 Alkyl, C 3-6 Alkenyl, C 3-6 The group consisting of alkynyl, benzyl, and any combination thereof; Ar 2 is selected from the group consisting of 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazolyl, quinolyl, 3,5-dimethylisoxazolyl, 2-methylthiazolyl, thiazolyl, 2-thienyl, 3-thienyl, pyrimidinyl, and any combination thereof; and q is an integer from 0 to 2.
5. The method according to claim 1, wherein R 1 and R 2 One or both of them are selected from the group consisting of amino acids, β-amino acids, sugars, or any combination thereof.
6. A method according to any one of the preceding claims, wherein R 4 C 1-6 alkyl.
7. A method according to any one of the preceding claims, wherein R 4 Selected from the group consisting of tert-butyl, 4-{N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino}benzyl ester (DMab), and combinations thereof.
8. The method according to any one of the preceding claims, wherein X is selected from the group consisting of halogens and sulfonates.
9. The process according to any one of the preceding claims, wherein X is selected from the group consisting of chlorine, fluorine, bromine, p-toluenesulfonate (OTs), mesylate (OMs) and triflate (OTf).
10. The method according to any one of the preceding claims, wherein the reducing agent is selected from the group consisting of NaBH3, NaBH3CN and Na(CH3COO)3BH.
11. The method according to any one of the preceding claims, wherein the compound of Formula I has a structure of Formula IA, Formula IB or Formula IC:
12. The method according to any one of the preceding claims, wherein the compound of formula II has the structure of formula II-A:
13. The method according to any one of the preceding claims, further comprising preparing the compound of formula I by: a) contacting a compound of formula III with a chelating agent for a period of time and under conditions effective to produce said compound of formula I: wherein M is a transition metal having a +2 oxidation state.
14. The method of claim 13, wherein M is selected from the group consisting of vanadium, manganese, iron, cobalt, nickel, copper and zinc.
15. The method according to claim 13 or 14, wherein the chelating agent is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) or a salt thereof, diethylenetriaminepentaacetic acid (DTPA) or a salt thereof, and hydroxyethylethylenediaminetriacetic acid (HEDTA) or a salt thereof.
16. The method according to claim 15, wherein the salt of EDTA is selected from the group consisting of Na2EDTA.H2O and CaNa2EDTA.
17. The method according to any one of claims 13 to 16, wherein the compound of formula III is a compound having a structure of formula III-A:
18. The method according to any one of claims 11 to 13, wherein the compound of formula III is a compound having a structure of formula III-B, formula III-C, formula III-D, formula III-E, formula III-F or formula III-G:
19. The method according to any one of claims 13 to 18, further comprising preparing the compound of formula III by: a) contacting a compound of formula IV with 9-fluorenylmethoxyphosgene for a period of time and under conditions effective to produce said compound of formula IV:
20. The method according to claim 19, wherein the compound of formula IV is a compound having a structure of formula IV-A:
21. The method according to claim 19 or 20, wherein the compound of formula IV is a compound having a structure of formula IV-B, formula IV-C, formula IV-D, formula IV-E, formula IV-F or formula IV-G:
22. The method according to any one of claims 19 to 21, further comprising preparing the compound of formula IV by: a) contacting a compound of formula V with a metal (II) source for a period of time and under conditions effective to produce said compound of formula IV:
23. The method of claim 22, wherein the metal (II) source is selected from the group consisting of a Ni (II) source or a salt thereof and a copper (II) source or a salt thereof.
24. A method according to claim 22 or 23, wherein the metal source is a copper (II) source or a salt thereof.
25. The method of claim 24, wherein the copper (II) salt is selected from the group consisting of copper chloride and copper sulfate.
26. The method according to any one of claims 22 to 25, wherein the compound of formula V is a compound having a structure of formula VA, formula VB or formula VC:
27. The method according to any one of the preceding claims, further comprising: a) contacting the compound of formula II with a compound of formula VI-A, formula VI-B or formula VI-C, an activating agent and a base to provide an intermediate: wherein AA is an optionally substituted amino acid; and R 5 is a resin; and b) contacting the intermediate with a deprotecting agent for a period of time and under conditions effective to produce a compound of Formula VII-A, Formula VII-B or Formula VII-C:
28. The method of claim 27, wherein the resin comprises a cleavable group.
29. The method of claim 38, wherein the cleavable group is selected from the group consisting of OH, carboxyl, and polystyrene resin.
30. The method according to any one of claims 27 to 29, wherein the activator is selected from the group consisting of: 1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbonium hexafluorophosphate (COMU), 1H-1,2,3-benzotriazol-1-yloxy)-tris(pyrrolidinyl)- Hexafluorophosphate (PyBOP), 1-hydroxy-7-azabenzotriazole (HOAt), 2-(1H-7-azabenzotriazol-1-yl)-1,1,3-tetramethyluronium hexafluorophosphate (HATU), benzotriazol-1-yl-oxy-tris(dimethylamino) Hexafluorophosphate (BOP), chloro-N,N,N',N'-tetramethylformamidine hexafluorophosphate, dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), ethyl cyano(hydroxyimino)acetate-O 2 ]Tri-1-pyrrolidinyl hexafluorophosphate (PyOxim), ethyl cyanohydroxyiminoacetate (Oxyma), N,N'-diisopropylcarbodiimide (DIC), N-hydroxybenzotriazole (HOBT), O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), O-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU), O-benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), and any combination thereof.
31. The method of any one of claims 27 to 30, wherein the deprotecting agent is a base.
32. The method of claim 31, wherein the base is selected from the group consisting of piperidine, 4-methylpiperidine, piperazine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and morpholine.
33. The method of any one of claims 27 to 32, wherein the amino acid is a natural amino acid.
34. The method of claim 33, wherein the natural amino acid is selected from the group consisting of arginine (Arg), histidine (His), lysine (Lys), aspartic acid (Asp), glutamic acid (Glu), serine (Ser), threonine (Thr), asparagine (Asn), glutamine (Gln), cysteine (Cys), selenocysteine (Sec), glycine (Gly), proline (Pro), alanine (Ala), valine (Val), isoleucine (Ile), leucine (Leu), methionine (Met), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp), and pyrrolysine.
35. The method of any one of claims 27 to 32, wherein the amino acid is selected from the group consisting of 4-aminobenzoic acid (PABA), alloisoleucine, allothreonine, carboxyglutamic acid, cystathionine, D-alanine, dehydroalanine, D-glutamic acid, diaminopimelic acid, leucine, glycine betaine, homocysteine, homonorleucine, homoserine, hydroxyglycine, hydroxyproline, hydroxyputrescine lysine, isoserine, isovaline, lanthionine, N-ethylalanine, N-ethylglycine, N-ethyl β-alanine, N-isopropylglycine, N-methylalanine, N-methyl β-alanine acid, norleucine, norvaline, N-propylglycine, O-methyl-homoserine, ornithine, pipecolic acid, pyroglutamic acid, sarcosine, selenocysteine, selenohomocysteine, selenomethionine, selenoethionine, taurine, tert-leucine, α,β-diaminopropionic acid, α,γ-diaminobutyric acid, α-aminoisobutyric acid, α-amino-n-butyric acid, α-amino-n-heptanoic acid, α-hydroxy-γ-aminobutyric acid, β-alanine, β-aminoisobutyric acid, β-amino-n-butyric acid, γ-aminobutyric acid, δ-aminolevulinic acid, 1-aminocyclopropane-1-carboxylic acid, azetidine-2-carboxylic acid, cycloleucine, and pseudoproline.
36. The method according to any one of claims 27 to 35, wherein the compound of formula VII is a compound having a structure of formula VII-A, formula VII-B or formula VII-C:
37. The method of any one of claims 27 to 36, further comprising contacting the compound of Formula VII-A, VII-B or VII-C with the compound of Formula II and the activating agent, respectively, and then contacting with the deprotecting agent for a period of time under conditions effective to produce the compound of Formula VIII-A, VIII-B or VIII-C:
38. The method of claim 37, further comprising contacting the compound of formula VIII-A, formula VIII-B or formula VIII-C with the compound of formula II and the activating agent, respectively, and then contacting with the deprotecting agent for a period of time under conditions effective to produce the compound of formula IX-A, formula IX-B or formula IX-C:
39. The method of claim 38, further comprising contacting the compound of Formula IX-A, Formula IX-B or Formula IX-C with the compound of Formula II and the activating agent, respectively, and then with the deprotecting agent under conditions and for a period of time effective to produce the compound of Formula XA, Formula XB or Formula XC:
40. The method of claim 39, further comprising contacting the compound of formula XA, formula XB or formula XC with the activator and YZ, respectively, wherein Y is aminocarbonyl; and Z is a leaving group, It is then contacted with the deprotecting agent for a period of time and under conditions effective to produce a compound of Formula XI-A, Formula XI-B or Formula XI-C:
41. The method of claim 40, wherein Y is selected from the group consisting of H and an amino acid.
42. The method of any one of claims 40 to 41, wherein Z is selected from the group consisting of halogen, sulfonate, and triazole.
43. The method according to any one of claims 40 to 42, wherein Z is selected from the group consisting of chlorine, fluorine, bromine, p-toluenesulfonate (OTs), mesylate (OMs), trifluoromethanesulfonate (OTf), N-hydroxybenzotriazolyl, 1-hydroxy-7-azabenzotriazolyl and The group composed of.
44. The method of any one of claims 40 to 43, further comprising contacting the compound of Formula XI-A with a weak acid for a period of time and under conditions sufficient to produce a compound of Formula XII-A:
45. The method of claim 44, wherein the time is between about 1 minute and about 24 hours.
46. The method of claim 45, wherein the time is between about 2 and about 12 hours.
47. The method of claim 44 or 46, wherein the temperature is between about room temperature and elevated temperature.
48. The method of claim 44 or 46, wherein the elevated temperature is at least about 60°C.
49. The method of any one of claims 44 to 48, wherein the weak acid is selected from the group consisting of trifluoroacetic acid, acetic acid, and any combination thereof.
50. The method of claim 39, comprising repeating the contacting step w times to provide a compound of Formula XV-A, Formula XV-B or Formula XV-C: in, w is an integer from 1 to 20.
51. The method of claim 50, wherein w is an integer from 1 to 8.
52. The method of claim 51, wherein w is an integer from 6 to 8.
53. A compound produced using the method according to any one of claims 1 to 52.
54. The compound of claim 53, wherein the compound is a compound having the structure of Formula XIV:
55. A method for preparing a compound of formula I: Where R 4 is a protecting group; x is an integer 1 or 2; and z is an integer 1 or 2; The condition is that x and z are not both 2; The method comprises contacting a compound of formula III with a chelating agent for a period of time and under conditions effective to produce a compound of formula I: wherein M is a transition metal having a +2 oxidation state.
56. A method for preparing a compound of formula III: Where R4 is a protecting group; x is an integer 1 or 2; and z is an integer 1 or 2; The condition is that x and z are not both 2; The method comprises contacting a compound of formula IV with 9-fluorenylmethoxyphosgene for a period of time and under conditions effective to produce the compound of formula III.
57. A method for preparing a compound of formula IV: The method comprises contacting a compound of formula V with a metal (II) source for a period of time and under conditions effective to produce the compound of formula IV:
58. A method for preparing a compound of formula VII: The method comprises contacting a compound of formula II with a compound of formula VI, an activating agent and a base to provide an intermediate: wherein AA is an optionally substituted amino acid; and R 5 is a resin; and The intermediate is contacted with a deprotecting agent and under conditions and for a time effective to produce the compound of Formula VII.
59. A method for preparing a compound of formula XV: Where R 1 Selected from optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 The group consisting of alkynyl, optionally substituted aryl, and any combination thereof; R 2 Absent or selected from H, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 The group consisting of alkynyl, optionally substituted aryl, and any combination thereof; or R 1 and R 2 Connect to form C 3-8 Cycloalkyl; R 4 is a protecting group; x is an integer 1 or 2; and z is an integer 1 or 2, provided that both x and z are not 2 at the same time; w is an integer from 1 to 20; and y is an integer 0 or 1; The method comprises: a) contacting a compound of formula II with a compound of formula VI, an activating agent and a base to provide an intermediate: wherein AA is an optionally substituted amino acid; and R 5 is a resin; and b) contacting the intermediate with a deprotecting agent for a period of time and under conditions effective to produce a compound of formula VII: c) contacting the compound of formula VII with the compound of formula II (w-1) times.
60. A compound of formula II or a pharmaceutically acceptable salt thereof: Where y is an integer 0 or 1; R 1 Selected from optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 The group consisting of alkynyl, optionally substituted aryl, and any combination thereof; R 2 Absent or selected from H, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 The group consisting of alkynyl, optionally substituted aryl, and any combination thereof; or R 1 and R 2 Connect to form C 3-8 Cycloalkyl, R 4 For the protecting group.
61. The compound according to claim 60, wherein R 1 and R 2 Independently by C 0-6 Alkyl OH, C 0-6 Alkyl SH, C 0-6 Alkyl NH2, C 0-6 Alkyl-OC 0-6 Alkyl, C 0-6 Alkyl-SC 0-6 Alkyl, C 0-6 Alkyl C(O)OH, C 0-6 Alkyl C(O)(C 1-6 Alkyl), C 0-6 Alkyl C(O)O(C1-6 Alkyl), C 0-6 Alkyl N3, C 0-6 Alkyl C(O)NH2, C 0-6 Alkyl-C(O)N(C 1-6 alkyl)OH, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 5-7 cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, -NHC(NH2)(=N(C 0-6 alkyl)), -NHC(NH2)(=S(C 0-6 alkyl)), nucleobase, or amino acid substitution; wherein any carbon atom of the alkyl, alkenyl or alkynyl group is optionally selected from O, S, SO, SO2 and NR 7 heteroatom substitution in the composed groups; R 7 Choose from H, C 1-4 Alkyl, C 3-4 Alkenyl, C 3-4 Alkynyl, C 1-4 The group consisting of a bridged alkyl group, and any combination thereof, wherein a bridge is formed between the nitrogen atom and the carbon atom of the chain containing the heteroatom, thereby forming a ring, and wherein the ring is optionally connected to Ar 1 condense; Ar 1 Selected from optionally substituted C 3-6 The group consisting of cycloalkyl, heterocyclyl, aryl, heteroaryl, and any combination thereof.
62. The compound according to claim 61, wherein Ar 1 is selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl and anthracenyl; or is a heterocyclic aromatic group selected from the group consisting of 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, 2-pyrazolyl, pyrazolidinyl, isoxazolyl, isotriazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5 -triazinyl, 1,3,5-trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolyl, benzo[b]furanyl, benzo[b]thienyl, 1H-indazolyl, benzimidazolyl, benzothiazolyl, purinyl, 4H-quinolizinyl, quinolyl, 1,2,3,4-tetrahydroquinolyl, isoquinolyl, 1,2,3,4-tetrahydroisoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and any combination thereof.
63. according to the compound described in claim 61 or 62, wherein Ar 1 Optionally H, halogen, OH, NO2, -SO3H, CF3, OCF3, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Alkoxy, OC 3-4 alkenyl, -O-benzyl, -O-phenyl, 1,2-methylenedioxy, -NR 5 R 6 、-C(O)OH、-C(O)NH(C 1-6 alkyl), -C(O)NH(C 3-5 alkenyl), -C(O)N(C 1-6 Alkyl)(C 1-6 alkyl), -C(O)(C 3-5 Alkenyl)(C 3-6 alkyl), morpholinyl, piperidinyl, -O-Ar 2 、-CH2-(CH2) q -Ar 2 、-O-(CH2) q -Ar 2 、-(CH2) q -O-Ar 2 , or -CH=CH-Ar 2 One or more substitutions in; R 5 and R 6 Independently selected from H, C 1-6 Alkyl, C 3-6 Alkenyl, C 3-6 the group consisting of alkynyl and benzyl; Ar 2 is selected from the group consisting of 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazolyl, quinolyl, 3,5-dimethylisoxazolyl, 2-methylthiazolyl, thiazolyl, 2-thienyl, 3-thienyl and pyrimidinyl; and q is an integer between 0 and 2.
64. The compound according to claim 60, wherein R 1 and R 2 One or both of them are selected from the group consisting of amino acids, β-amino acids and sugars.
65. A compound according to any one of claims 60 to 64, wherein R 4 C 1-6 alkyl.
66. A compound according to any one of claims 60 to 65, wherein R 4Selected from the group consisting of tert-butyl and 4-{N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino}benzyl ester (DMab).
67. A compound according to any one of claims 60 to 66, wherein the compound of Formula II is a compound having a structure of Formula II-A, Formula II-B or Formula II-C:
68. A compound having the following structure:
69. A compound having the following structure:
70. A compound having the following structure:
